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Introduction 
Introduction 
 
Disseminated fungal infections remain one of the major problems in modern 
chemotherapy. In the last two decades a dramatic increase in the latter infections has 
been observed and incidence rates up to 36% have been reported in particular 
patient populations. This increase was associated with an increasing number of 
immuno-compromised individuals mainly due to organ transplantation, HIV infection, 
cancer patients, corticosteroid therapy, diabetes. Other underlying diseases were 
also recognized as predisposing factors (6). The most common pathogens that are 
involved include Candida species, Cryptococcus neoformans, Histoplasma 
capsulatum, and Aspergillus species. Other uncommon organisms also implicated in 
invasive human infections include members of the zygomycetes, Fusarium spp. and 
Scedosporium spp. (1). 
There is a very limited number of antifungal agents for treatment of invasive fungal 
infections. The mode of action can be divided into those that block the ergosterol 
formation, such as the azoles, and those that bind the ergosterol present in the fungal 
membrane, such the polyenes, and by inhibition of the DNA such as flucytosine. In 
the recent years new compounds have been developed, such as the candins, for 
which the target is the cell wall. The toxicity varies with amphotericin B being the 
most toxic and the azoles, that are less toxic but also less effective (5). On the other 
hand, the emerging challenge of multi-drug resistance (MDR) makes the situation 
even worse. Resistance to antifungal azoles has been studied in yeasts and molds 
especially in Candida albicans and Aspergillus fumigatus. Resistance mechanisms 
include changes in cellular content of the azole, mutation in sterol desaturation during 
the ergosterol biosynthesis and mutation in or elevated levels of 14α-demethylase (8, 
10). Thus, searching for other alternatives than the existing drugs is mandatory. In 
this respect, since fungi are eukaryotic cells, many pathways are shared with human 
cells, such as the calcium metabolism and its binding protein calmodulin, that 
regulates many intracellular processes, including proliferation or differentiation of 
human and fungal cells. Traditionally, drug discovery has been based on identifying 
agents that kill microorganisms in vitro with the expectation that these agents will be 
effective in vivo. This approach involves screening of many classes of synthetic and 
natural products against a variety of fungi, and has proved successfull for a variety of 
antimicrobial compounds, including antifungal agents. 
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 Thus, it could be of interest to re-evaluate some antibiotics and other drugs that 
posses other targets or different properties as starting points for new drug 
development.  
Combination therapy has been shown to be beneficial for several difficult-to-treat 
infections such as HIV, mycobacterial infections and disseminated cryptococcosis (2, 
4,9). In addition, combination of conventional antifungal compounds with potential 
new targets might be useful to eliminate natural resistance to specific antifungal 
drugs, to enhance the activity of the conventional agents or to reduce their toxicity. 
However, the intensity of drug interactions in vitro depends both on the methodology 
used (7) as well as on the approach used to analyze the results (3). The most 
common approach in antifungal susceptibility testing is the microdilution 
checkerboard technique. According to this technique a serial dilution of drug A is 
combined with a serial dilution of drug B (including zero concentrations of each drug) 
in small volumes of broth medium in microtitre plates in such a way to obtain a two-
dimensional checkerboard (7). In vitro systems are needed in order to help to predict 
drug interaction in clinical practice using the fungal strain that caused the infection. In 
vitro and in vivo data, should be combined  in order to optimize for instance the 
dosing of regimens in drug combination therapy.  
Thus, the aim of this thesis was to evaluate the in vitro activity of agents with 
antifungal activity alone or in combination with conventional antifungal drugs. 
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Introduction 
 
Aim of the thesis 
 
In order to have more therapeutic options to treat patients suffering from fungal 
infections we investigated the activity of a variety of compounds alone or in 
combination with conventional antifungal agents against a selection of common and 
uncommon fungal pathogens. 
This study was carried out in terms of minimal inhibitory concentration (MIC), minimal 
fungicidal concentration (MFC) and drug combination. A variety of drugs were 
evaluated against yeast and molds including, antibacterial drugs such as quinolones, 
rifampicin and sulfas, antiparasitic agents such as pentamidine, antiarrhythmic  and 
antihypertensive agents such nifedipine and amiodarone; proton pump inhibitors 
such as lansoprazole and antipsychotic agents like chlorpromazine, trifluopherazine 
and chlorprothixene against difficult-to-treat yeasts and molds. 
Potentiation of the antifungal effect by drug combinations would be also very useful, 
to decrease side effects or increase the efficacy of the drugs against (resistant) 
microorganisms. Combination of different classes of compounds could represent a 
novel approach. 
Chapter 1 is focused on the antifungal activity of non-antifungal agents against  
fungal pathogens. 
In Chapter 1.1 the antifungal properties of compounds such as chlorpromazine, 
proton pump inhibitors, antiarrhythmics, cholesterol-lowering agents, antineoplastic 
and immunosuppressive agents, antiparasitic drugs and antibiotics are reviewed. 
In Chapter 1.2,  the in vitro susceptibility of 70 strains of Aspergillus species was 
tested against 8 different sulfa drugs, including sulfamethoxazole, co-trimoxazole, 
sulfadiazine, dapsone and pentamidine, with a microdilution method using RPMI 
1640 and yeast nitrogen base media. Because invasive aspergillosis is encounted 
relatively infrequently in HIV-infected patients, we hypothised that prophylaxis for 
Pneumocystis carinii pneumonia (PCP) might also prevent invasive Aspergillus 
infections. A literature review for cases of invasive aspergillosis in HIV-infected 
patients that developed during prophylaxis for PCP is described in chapter 1.3. In 
Chapter 1.4 the in vitro activity of eight different antipsychotic drugs against 200 
fungal isolates was investigated including Candida species with reduced 
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susceptibility to azoles, such as C. albicans, C. krusei and C. glabrata, Aspergillus, 
zygomycetes, Scedosporium apiospermum and S. prolificans. 
Chapter 2 focusses on the in vitro interaction between antifungal agents and other 
compounds against different molds. 
The in vitro interaction between amphotericin B and either rifampicin, 5-
fluorocytosine, or terbinafine, and between terbinafine and voriconazole is studied 
against 35 strains of zygomycetes (Chapter 2.1). In chapter 2.2 the in vitro 
interaction between amphotericin B and pentamidine against 30 clinical isolates of S. 
prolificans is evaluated using a checkerboard microdilution method and the 
interaction between the drugs is analyzed using fractional inhibitory concentration 
index (FICI) analysis and response surface modeling. 
Due to the long treatment needed and frequent occurrence of relapses of infections 
caused by black fungi the combination of quinolones and sulfadiazine could 
represent a better approach than monotherapy. Therefore the in vitro combined effect 
of antifungal and antibacterial drugs using the checkerboard technique was 
investigated against clinical Exophiala spinifera strains in chapter 2.3.  
In Chapter 2.4 we describe the in vitro interaction between itraconazole and seven 
different nonantimicrobial membrane compounds against seven itraconazole 
susceptible and seven itraconazole resistant A. fumigatus strains. 
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Abstract 
The antifungal activity of synthetic, nonchemotherapeutic compounds, antineoplastic 
agents and antibacterial drugs, such as sulphonamides, has been known since the 
early 20th century (1932). In this context, the term "nonantifungal" is taken to include 
a variety of compounds that are employed in the management of pathological 
conditions of nonfungal infectious etiology but have been shown to exhibit broad-
spectrum antifungal activity. In this review, the antifungal properties of compounds 
such as chlorpromazine, proton pump inhibitors, antiarrhythmics, cholesterol-lowering 
agents, antineoplastic and immunosuppressive agents, antiparasitic drugs and 
antibiotics are described. Since fungi are eukaryotic cells, they share many pathways 
with human cells, thus increasing the probability of antifungal activity of "nonfungal 
drugs". The potential of these drugs for treatment of fungal infections has been 
investigated sporadically using the drugs alone or in combination with "classic" 
antifungal agents. A review of the literature, supplemented with a number of more 
recent investigations, suggests that some of these compounds enhance the activity 
of conventional antifungal agents, eliminate natural resistance to specific antifungal 
drugs (reversal of resistance) or exhibit strong activity against certain fungal strains in 
vitro and in animal models. The role of these agents in the epidemiology and in the 
clinical manifestations of fungal infections and the potential of certain drugs for 
treatment of invasive fungal infections require further investigation. 
 
Chapter 1.1 
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Introduction 
 
Due to the progress made in the fields of intensive care, haemato-oncology and 
transplantation in particular, the number of immunocompromised patients has 
increased. Although modern antibacterial chemotherapeutic agents contribute a great 
deal to improved prognosis, increasing numbers of immunocompromised patients are 
at risk for systemic fungal infection. The rapidly increasing number of HIV infections 
worldwide presents another group of immunocompromised hosts susceptible to 
fungal infections [1]. Fungal infections have long been a major therapeutic challenge. 
The therapeutic arsenal has been limited, and the use of drugs has been restricted 
due to toxicity or unfavorable pharmacokinetic profiles. Furthermore, resistance has 
been observed, mainly following treatment of Candida albicans infections in HIV-
infected patients with the triazole fluconazole, which is currently the most frequently 
used antifungal in this situation [2]. There is also some evidence that the spectrum of 
fungal pathogens involved in human infection is shifting from Aspergillus fumigatus 
and Candida to uncommon fungi such as non-albicans Candida species, azole-
resistant Candida albicans, and Fusarium, Trichosporon and Alternaria species [3]. 
The activity of conventional and new antifungal agents against these pathogens is 
limited or unknown. There is evidence that some drugs targeted at pathogens other 
than fungi exhibit antifungal activity. In addition, drugs used for the treatment of 
conditions other than infectious diseases might exhibit antifungal activity since fungi 
and human cell share common pathways, both being eukaryotic. This is of interest 
since these drugs might be useful for treatment of fungal infection alone or in 
combination or interact with potentially new targets. In this review, the antifungal 
activity of nonantifungal agents alone or in combination with classic antifungal drugs 
is discussed. 
 
 
Targets of non-antifungal agents 
Pumps located in the cell membrane are present in order to control the homeostasis 
between the intra and extra-cellular compartment. Pumps are also present in the 
endoplasmic reticulum. The concentration of free calcium in the cell is regulated and 
is essential for cell multiplication, transport, elongation and growth. The calcium 
Antifungal activity of non-antifungal drugs 
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pumps can be blocked by antiarritmic drugs, β-blockers, antiparasitic drugs, 
antipsychotic drugs, proton pump inhibitors and immunosuppressive agents. Others 
compounds can interfere with the DNA division or formation and alter protein 
synthesis. These compounds include quinolones, sulphonamides and antineoplastic 
drugs. Protein synthesis can be neutralized by inhibition of encoding RNA, especially 
by drugs that interact with these targets such as rifampicin, tetracycline and 
macrolides. Since these agents could have multiple sites of action, effects can be 
observed simultaneously or in a concentration-dependent fashion. Potential targets 
for nonantifungal drugs are summarized in Fig. 1. 
 
 
 
 
In the following, different classes of nonantifungal drugs are reviewed.  In general, 
the drugs that inhibit fungal growth at high concentrations in vitro are considered to 
be ineffective in vivo. 
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Antipsychotic drugs 
 
Phenothiazines are antipsychotic drugs that have multiple effects, including 
modification of membranes, alteration of cyclic nucleotide metabolism and 
intercalation into DNA. They also bind to calmodulin, which regulates many 
intracellular processes. The phenotiazine chlorpromazine has fungistatic and 
fungicidal activity against Candida albicans in vitro [4]. It has been shown that the 
minimal inhibitory concentration of 2 µg/ml also inhibits the germ tube formation. 
Chlorpromazine in combination with amphotericin B displayed synergistic interaction 
[4]. Like chlorpromazine, trifluopherazine also exhibited in vitro activity against 
Candida tropicalis, Candida parapsilosis, Candida glabrata and Cryptococcus 
neoformans, with MIC values ranging from 10 to 30 µg/ml. In murine models of 
invasive candidiasis and cryptococosis, these drugs increased survival compared 
with that of controls, even at low dosages. Plasma concentrations of the drugs in 
humans vary between 0.1 and 0.5 µg/ml. The drugs accumulate in the central 
nervous system (CNS), resulting in levels 70-fold higher than those in plasma. 
Therefore, the drugs would be potentially useful for treatment of CNS fungal 
infections [5]. Flunarizine, a potent channel blocker, was evaluated in combination 
with ketoconazole in vitro against 138 clinical yeast isolates, including Candida 
glabrata and Candida krusei. The interaction was synergistic against all isolates [6]. 
  
 
In Vitro Data Drug in combination Drug Microorganism 
(n) MIC MFC Drug Result 
Reference 
 
AMB: Amphotericin B; ; KTZ: Ketoconazole; ADD: Additive affect;  
MIC, minimal inhibitory concentration. MFC, minimal fungicida l concentration.   
Candida spp (5) 17.5-35 
µg/ml
35µg/ml AMB ADD [4]
Candida spp (4) 10-40µg/ml
Chlorpromazine
C. neoformans 
(1)
10-40µg/ml
Candida spp (4) 20-40µg/mlTrifluopherazine
C. neoformans 
(1)
10-40µg/ml
[5]
Flunarizine Candida spp 
(138)
45-319µg/ml KTZ ADD [6]
Antifungal activity of non-antifungal drugs 
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Antiarrhythmic drugs and Beta-Blockers 
Calcium and its binding protein calmodulin are known to modulate the proliferation, 
differentiation and metabolism of a variety of cell types. Calcium channel antagonists 
influence the calmodulin system. The concentration of free intracellular calcium can 
be increased in eukaryotic cells by opening the voltage-dependent calcium channels 
(VDCC), allowing extracellular Ca2+ to enter the cell. Several chemically distinct 
classes of organic compounds share the ability to inhibit calcium influx by blocking 
the calcium channels. These channels are present in yeasts and moulds and 
therefore are a potential target for new antifungal compounds. 
Cinnarizine, verapamil, nifedipine and nimodipine alone or in combination with 
ketoconazole were tested against clinical isolates of Candida albicans. These drugs 
alone exhibited antifungal activity in vitro at high concentrations; verapamil was more 
active than cinnarizine or nimodipine alone [7]. In combination, however, the activity 
of ketoconazole was potentiated [7]. This drug and local anesthetics such as 
lidocaine, bupivacaine and ropivacaine inhibited Candida germ tube formation, and 
this effect was dose dependent and pH independent. The addition of calcium 
reversed the effect [8, 9]. Intracellular free calcium ions are thought to be an 
important second messenger for many neutrophil functions, including phagocytosis, 
so many of these calcium blockers that have antifungal action may also block the 
killing activity of human monocytes, thereby limiting the potential use for treating 
invasive fungal infection. 
Although pharmacological concentrations of verapamil, nifedipine and diltiazem 
inhibited the killing activity in polymorphnuclear leucocytes (PMNs) and monocytes 
against Candida albicans, the fungicidal activity of the phagocyte cell was not 
affected in patients treated with calcium blockers [10]. The activity of β-blockers 
(nadolol, penbutolol, propranolol and bunitrolol) and fluconazole was investigated in 
vitro and in a murine model of invasive candidosis. Nadolol and other β-blockers 
were ineffective in vitro and did not significantly prolong survival in vivo. Bunitrolol, 
propranolol and penbutolol, which were active in tests in vitro, did exhibit activity in 
vivo. Monotherapy with propranolol appeared efficacious in a mouse model, doubling 
the survival. Treatment with bunitrolol resulted in a 60–100% increase in survival in 
two different experiments. Only treatment with carteolol was toxic, causing 
deterioration of the general condition of the animal. The survival of infected mice 
Chapter 1.1 
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receiving a low dose of fluconazole combined with propranolol doubled compared to 
those receiving fluconazole alone, and histological examination confirmed the 
inhibitory effect of the combination [11]. 
 
Proton Pumps  Inhibitors  
Another target for antifungal drugs is the plasma membrane H+-ATPase, which is well 
characterized and is present in the membrane of Candida albicans, Saccharomyces 
cerevisae, Cryptococcus neoformans and Aspergillus niger [12, 13, 14, 15]. The 
proton pump inhibitors that block these pumps either act as agents with antifungal 
activity or reverse acquired resistance to azoles. Omeprazole, lansoprazole, AG200, 
CAN-296 and NC1175 are compounds that can block this pump, thereby displaying a 
variety of antifungal effects. Omeprazole exhibited antifungal activity against 
Saccharomyces [16, 17]; CAN-296 had fungicidal activity against Candida spp. [18]; 
the novel benzoimidazole Ag 2000 inhibited the hyphae formation of Candida 
albicans in vitro [17] and a conjugated styryl ketone had potent fungicidal activity 
against yeasts and moulds, including Candida spp., Cryptococcus neoformans, 
Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger and Aspergillus nidulans 
[19, 20, 21]. More data, especially animal models, are needed to confirm the in vitro 
activity. 
In Vitro Data Drug in combinationDrug Microorganism
(n) MIC MFC Drug Result
Reference
KTZ: Ketoconazole; SYN: Synergist ic 
MIC, minimal inhibitory concentration. MFC, minimal fungicida l concentration.   
Cinnarizine 85-950µg/ml KTZ SYN
Verapamil 55-1050µg/ml
1.5 mg/ml
Nifedipine 55-1050µg/ml
4mg/ml
Nimodipine
Candida spp 
(66)
85-1050µg/ml
Lidocaine Candida spp 
(20)
50-40 mg/ml
Propanolol C. albicans (3) 1-5 mM
[7, 8, 9]
In Vitro Data Drug in combinationDrug Microorganism
(n) MIC MFC Drug Result
Reference
MIC, minimal inhibitory concentration. MFC, minimal fungicida l concentration.   
CAN-296 Candida spp (5) 0.15-10µg/ml [18]
AG2000 
(lansoprazole)
C. albicans (3) 200 uM [17]
Omeprazole C. albicans 
Saccharomyces 
spp (8)
0.43 mM [16]
0.25-2µg/ml 2µg/ml
0.8-1.33µg/ml
1.33-2µg/ml
NC1175 C. neoformans 
(15)
Candida spp (4)
Saccharomyces 
spp(6)
Aspergillus spp (4)
2.92-
11.68µg/ml
[19, 20, 
21]
Antifungal activity of non-antifungal drugs 
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Antineoplastic Agents 
Cisplatinum is an effective chemotherapeutic agent for treatment of many sorts of 
solid tumours. Its cytotoxicity derives primarily from its ability to form DNA adducts 
that cross-link with neighbouring purine residues. The drug was active against 
Candida albicans in vitro [22, 23] and showed an inhibitory effect at concentrations as 
low as 40 µg/ml [24, 25]. In Candida albicans, pretreatment of cells with amphotericin 
B or miconazole resulted in an increment of the activity of cisplatinum. This might be 
due to synergistic interaction, but additional in vitro and in vivo experiments are 
needed to confirm this positive relation. 
The MICs of methotrexate, cyclophosfamide, vincristine, bleomycin and doxorubicin 
are between 500 and 1,500 µg/ml against Candida albicans, Candida tropicalis, 
Candida parapsilosis, Candida krusei, Candida kefyr, Candida glabrata and 
Trichosporon [26]. Among these agents, bleomycin and doxorubicin appear to be the 
most active against Candida tropicalis. However, even though bleomycin is toxic to 
yeasts in vitro, no antifungal activity was found in an animal model [27]. 
In addition, variety of different antineoplastic drugs (methotrexate, cyclophosphamide 
and 5-fluorouracil) were evaluated in vitro alone and combined with amphotericin B, 
flucytosine and miconazole against different Candida spp. and Trichosporon. 
Effective combinations were active against multiple fungal species, but the ratios of 
drugs at which optimal interaction was achieved varied. In general, a polyene 
combined with methotrexate, doxorubicin or 5-fluorouracil exhibited synergistic 
interaction against yeasts. This might be due to the membrane perforation caused by 
amphotericin B, thus allowing the second drug to penetrate into the cell. However, 
drugs such as cyclophosphamide and bleomycin antagonized the antifungal activity 
of the polyene [26]. 
There have been no clinical studies that suggest that any of the antineoplastic agents 
presently used in clinical practice have a positive impact on either preventing or 
treating fungal infections. On the other hand, many of the targets for these drugs 
have homologues in the eukaryotic fungal pathogens, and a careful examination of 
these classes of drugs may lead to the development of novel selective antifungal 
drugs [28, 29]. 
Antineoplastic drugs might potentiate the activity of antifungal agents, but the 
possible clinical relevance of this observation is unknown. 
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Immunosuppressive Drugs 
Cyclosporine A (CsA), tacrolimus (TcS) and sirolimus were originally developed for 
their antifungal activity but were later found to possess immunosuppressive 
properties [30]. The target of these drugs is calcineurin, which regulates cell cycles, 
hyphae elongation, vegetative growth, cation homeostasis and cell wall synthesis and 
also plays an essential role in the regulation of the intracellular Ca2+ concentration 
[31]. These drugs suppress the immune system by inhibiting calcineurin. CsA is 
markedly toxic in vitro to the opportunistic fungal pathogen Cryptococcus neoformans 
at 37°C but not at 24°C [32]. CsA was also active against Cryptococcus immitis at 
1 µg/ml but did not inhibit the mycelial phase of two other diphasic pathogenic fungi, 
Histoplasma capsulatum and Blastomyces dermatitidis, even at concentrations up to 
10 µg/ml. There are no data available about the in vitro activity of this drug against 
the yeast-form of these pathogens [33]. CsA was active against Aspergillus niger but 
not against Aspergillus fumigatus and Aspergillus flavus [33]. In order to decrease the 
immunosuppressive activity of these compounds, many investigators produced CsA 
and TcS analogues that exhibited antifungal activity without the immunosuppressive 
action. CsA and sirolimus analogues were tested against Cryptococcus neoformans. 
The MICs ranged from 0.39 to 1.56 µg/ml, and CsA displayed fungicidal activity at 
37°C, even against fluconazole-resistant clinical isolates of Cryptococcus 
neoformans [34]. 
A number of mechanisms of azole resistance in Candida albicans have been 
described [2, 35, 36, 37]. One of the most important was the energy-dependent drug 
In Vitro Data Drug in combinationDrug Microorganism
(n) MIC MFC Drug Result
Reference
AMB: Amphotericin B; FCZ: Fluconazole; KTZ: Ketoconazole; 
SYN: Synergistic effect; ADD: Additive af fect;ANT: Antagonistic effect 
MIC, minimal inhibitory concentration. MFC, minimal fungicida l concentration.   
Methotrexate Candida spp (7) 400-
1800µg/ml
Cyclophosphamide 250-
1250µg/ml
5-fluorouracil 78-312µg/ml
AMB
KTZ
FCZ
SYN 
ADD
ANT
[26]
Candida 
albicans (2)
0.39-
12.5µg/ml
1-12.5 
µg/ml
Bleomycin
C. neoformans 
(2)
0.19µg/ml 1.57µg/ml
[27]
C. albicans (1) 28µg/ml [24]
C. albicans (12) 0.172-0.320 
mM
[25]
Cisplatin
C. albicans (2) 50µg/ml [23]
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efflux mechanism. Multidrug resistant (MDR) and Candida drug resistant (CDR) 
genes encode for a putative transmembrane pump that plays an important role in the 
resistance against antifungal agents [38]. Maesaki et al. [39] investigated the 
combined effect of azole antifungal agents and MDR inhibitors such as TcS against 
azole-resistant strains of Candida albicans. They found synergistic effects especially 
between itraconazole-resistant Candida strains and TcS in vitro [39]. Moreover, 
Marchetti et al. [40] demonstrated the synergistic in vitro interaction between 
fluconazole and CsA using different in vitro techniques, including disk diffusion 
assays, checkerboard microtitre plate testing and time-kill curves against Candida 
albicans. 
CsA was effective in preventing infection when treatment was started on the day of 
infection in a murine model of coccidioidomycosis, even when the mice were 
inoculated with 1,000 times the 50% lethal dose of arthroconidia. Furthermore, good 
activity was observed in disseminated infection at a dose as low as 25 mg/kg [33]. 
CsA was also shown to exacerbate the course of cryptococcal meningitis in rabbits, 
even though it does not penetrate into the CNS [41]. Odom et al. [32] demonstrated 
that TcS failed to control cryptococcal meningitis in a rabbit model. 
In a model of invasive aspergillosis, survival was significantly prolonged using TcS or 
sirolimus compared to CsA. Histological examination revealed widely disseminated 
Aspergillus hyphae in the brains of CsA-treated mice, whereas the brains of TcS- or 
sirolimus-treated mice showed an almost total absence of hyphae. This finding is in 
keeping with the pharmacokinetics and the in vitro evaluation of these drugs [42]. 
Fluconazole and CsA treatment was tested in an experimental endocarditis model 
due to Candida albicans, resulting in successful eradication of the infection. The 
combination was fungicidal at therapeutic ranges. In contrast, amphotericin B was 
fungicidal in vitro but failed to resolve the endocarditis infection, indicating that the 
combination was more effective than amphotericin B alone [43]. 
Variables influencing the outcome of Cryptococcus neoformans infection in organ 
transplant recipients have been evaluated by Husain et al. [44]. In a series of 78 
cases of cryptococcal infection, patients receiving TcS were significantly less likely to 
have CNS involvement than patients receiving non-TcS-based immunosuppressive 
regimens (78% vs. 11%, P=0.001). Patients who received TcS had significantly more 
skin, soft tissue or osteoarticular involvement than those who received CsA therapy 
(66% vs. 21%, P=0.006). These results might reflect the different levels of 
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penetration of the drugs in different tissues, including the CNS. This initial 
observation was confirmed by other studies. Moreover, patients receiving TcS had a 
significantly higher probability to have early-onset infection than those receiving other 
immunosuppressive drugs. The mortality did not differ for early- versus late-onset 
cryptococosis [45, 46]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A retrospective analysis of liver transplant recipients suggested that TcS could be of 
clinical importance. In this study, invasive aspergilosis was diagnosed in only 0.2% of 
TcS recipients versus 2.4% of controls given CsA (P<0.01), [47] but prospective 
clinical trials are necessary to confirm this observation. 
The clinical impact of the kind of immunosuppressive agent used on the presentation 
of fungal infection was not evaluated for other invasive fungal infections caused by 
susceptible pathogens, including Candida and Fusarium. The impact of the antifungal 
activity of these drugs, particularly with regard to clinical relevance, remains to be 
determined. 
 
 
Antibacterial Agents 
Antimicrobial drugs such us sulphonamides, rifampicin, macrolides and quinolones 
were studied alone or in combination with polyenes or azoles in vitro, in animal 
In Vitro Data Drug in combination Drug Microorganism 
(n) MIC MFC Drug Result 
Reference
FCZ: Fluconazole;  ITZ: Itraconazole; SYN: Synergistic  MI C, minimal inhibitory concentration. MFC, minimal fungicidal concentration.   
C. albicans (3) >10µg/ml FCZ SYN [40] 
C. alb icans (2) >10µg/ml FCZ SYN [43] 
C. neoformans 
(3) 
0.39-
0.78µg/ml
25-
312µg/ml
[34] 
Cyclosporine A 
And non - 
immunosuppressive 
Cyclosporine - like 
drugs C. neoformans 
(2) 
>10µg/ml
Aspergillus spp 
(3) 
1->10µg/ml
H. capsulatum (1)
B. dermatitidis 
(1) 
>10µg/ml
C. immitis (8) 1µg/ml
[33] 
FCZ SYN C. albicans (3) >10-7-10-
3mM ITZ SYN 
[39] 
0.01µg/ml 0.09 µg/ml
Tacrolimus 
And non - 
immunosuppressive 
like 
C. neoformans 
(7) 3.12-6.25 
µg/ml
3.12-
12.5µg/ml
[32] 
Sirolimus C. albicans (9) 0.19µg/ml 0.39µg/ml
C. neoformans 
(5) 
>100µg/ml >100µg/ml
[34] 
drugs 
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models and in clinical trials. 
Sulpha drugs have been used for antimicrobial chemotherapy since their discovery in 
1932 [48]. Microbial growth is inhibited by interfering with the folic acid synthesis. The 
subsequent decrease in folic acid and microbial nucleotides inhibits the growth [48, 
49]. In vitro, sulpha drugs have an inhibitory effect against a broad spectrum of gram-
positive and gram-negative bacteria as well as Actinomyces, Chlamydia, Plasmodium 
and Toxoplasma [49]. The combination trimethoprim-sulfamethoxazole was active 
against Paracoccidioides brasiliensis in vitro [50]. In a comparative randomized trial, 
sulfadiazine was equally effective as itraconazole or ketoconazole in patients with 
moderately severe paracoccidioidomycosis [51]. Ketoconazole in combination with 
sulfamethoxazole was synergistic against Candida albicans [52]. 
Sulpha drugs are extensively and successfully used in the treatment and prevention 
of Pneumocystis carinii pneumonia (PCP) in immunocompromised patients [53]. 
Pneumocystis carinii now is considered to belong to the fungal kingdom on the basis 
of genome analysis. Sulpha drugs were active against Aspergillus spp. 
Sulfamethoxazole and sulfamethoxypyridazine were found to be active against most 
of the Aspergillus species tested except Aspergillus ustus and Aspergillus terreus 
[54]. We have recently shown that sulfamethoxazole might help to prevent invasive 
aspergillosis in AIDS patients [55]. 
Rifampicin is a macrocyclica antibiotic produced by Streptomyces mediterranei. 
Alone, the drug does not produce any effect on fungal growth, but in combination with 
amphotericin B, synergistic interaction was observed in vitro against yeasts [56, 57, 
58, 59, 60] and dimorphic fungi such as Histoplasma capsulatum or Coccidioides 
immitis [61, 62] and Aspergillus spp. [63, 64, 65]. Using time-kill curves, amphotericin 
B and rifampicin interacted synergistically against Cryptococcus neoformans [66]. 
The combination acted synergistically against most zygomycetes, including 
Rhizopus, Absidia, Mucor, Rhizomucor and Cunninghamella [67]. DNA 
topoisomerases, a class of enzymes that changes the topology of DNA, have been 
shown to be a target of many therapeutic agents, including the quinolones. Shen et 
al. [68] demonstrated that Candida albicans and Aspergillus niger possess high 
levels of both type I and II topoisomerases and therefore could be susceptible to 
agents that interact with that target. Nakajima et al. [69] have reported that 
investigational quinolones augmented the activity of amphotericin B against Candida 
albicans, Candida tropicalis, Cryptococcus neoformans and Aspergillus fumigatus. 
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The combination with fluconazole was synergistic only against Candida albicans in 
vitro [69]. This result is supported by a murine model of invasive candidiasis in which 
both amphotericin B and fluconazole in combination with quinolones prolonged 
survival. The quinolones alone were totally ineffective [69]. In another study, 
amphotericin B or fluconazole in combination with trovafloxacin or ciprofloxacin was 
not synergistic using checkerboard analysis. However, in an animal model of invasive 
candidiasis, the survival of mice treated with low-dose fluconazole (40 mg/kg/day) 
was only 10%, while 50% of the mice treated with fluconazole at 80 mg/kg/day 
survived. Survival of mice treated with low-dose fluconazole in combination with 
ciprofloxacin was equivalent to that of those receiving high-dose fluconazole [70]. 
Ciprofloxacin or trovafloxacin in combination with amphotericin B provided more 
protection against the infection than the drugs alone. Trovafloxacin extended survival 
up until 26 days, although all mice eventually died. Synergistic interaction was also 
observed against fluconazole-resistant Candida strains, including Candida albicans, 
Candida krusei and Candida glabrata [70]. 
 
 
In Vitro Data Drug in combinationDrug Microorganism
(n) MIC MFC Drug Result
Reference
AMB: Amphotericin B; FCZ: Fluconazole; KTZ: Ketoconazole;  
SYN: Synergistic ef fect; ADD: Additive affect; IDD: Indifferent effect.  
MIC, minimal inhibitory concentration. MFC, minimal fungicida l concentration.   
Rifampicin Zygomycetes 
(35)
>16µg/ml AMB SYN [67]
A. fumigatus 
(17)
AMB SYN
A. flavus (9)
A. niger (5)
>1000µg/ml [63]
C. neoformans 
(5)
AMB SYN>5 µg/ml [66]
DU-6859ª Candida spp 
(8)
AMB SYN/ADD
C. neoformans 
(1)
FCZ SYN
A. fumigatus 
(3)
>100 µg/ml [69]
Trovafloxacin Candida spp 
(8)
>250µg/ml AMB ADD [70]
A fumigatus (2) FCZ IDD/SYN
R. oryzae (2) AMB SYN
P. boydii (2)
Azithromycin Fusarium (26) >128µg/ml AMB SYN [75]
Aspergillus spp 
(70)
61.2 µg/ml >320µg/ml [54]Sulphamethoxazole
C. albicans (5) 50µg/ml KTZ SYN [52]
P. brasiliensis 
(4)
200-
1000/>2000
µg/ml
[50]Cotrimoxazole
57.1µg/ml >320µg/ml
Sulphamethoxypyridazine 108µg/ml >320µg/ml
Sulphadiazine
Aspergillus spp 
(70)
123.8µg/ml >400µg/ml
[54]
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Using checkerboard analysis the interaction between ofloxacin and fluconazole 
against azole-resistant C. albicans was not synergistic, but the intracellular 
concentration of rhodamine 6G was significantly increased in these strains when they 
were exposed to both drugs. The combination failed to prolong survival of mice but 
CFU counts in the tissues were reduced in the mice treated as opposed to those 
receiving mono-therapy [71]. 
Combination therapy of fluconazole with the quinolones also had beneficial effects in 
prolonging survival in mice infected with Rhizopus oryzae [72].  
Tetracycline, a protein synthesis inhibitor, possesses  no intrinsic antifungal activity, 
but synergy with amphotericin B has been demonstrated in vitro and in an animal 
model against C. immitis  [73, 74]. Amphotericin B combined with azithromycin  was 
synergistic in vitro against 26 clinical isolates of Fusarium, a fungus that in general is 
refractory to currently available antifungal drugs, leading to high mortality. 
Azithromycin was inactive alone but in combination decreased the MIC of 
amphotericin B by 2 to 8 fold [75].   
 
Antiparasitic Drugs 
Chloroquine is a weak base with over 60 years of clinical use for the treatment of 
malaria and rheumatologic diseases. This antiprotozoal drug is derived from 
quinacrine. Both drugs are concentrated within the acid food vacuole of the malaria 
parasites. Very high concentrations of these compounds have been found to inhibit 
the growth of S. cerevisiae [76]. Concentrations of 10 µM, enhanced the antimicrobial 
activity of human phagocytes against Cryptococcus neoformans in ex-vivo 
experiments. Chloroquine protected mice against invasive Cryptococcus infection 
compared with the control using BALB/c or SCID (severe combined 
immunodeficiency) mice [77]. In another study, 30 µM of chloroquine inhibited 
cryptococcal growth, and ≥100 µM was fungicidal in vitro, especially at pH 7, but this 
effect disappeared at pH 5. Quinacrine was found to be 10- to 100-fold more active 
than chloroquine, 1 µM of this drug inhibited fungal growth and 5 µM was fungicidal. 
Quinacrine also significantly enhanced the anticryptococcal activity of human 
monocytes. [78, 79]. 
Chloroquine inhibits the intracellular growth and induces the killing of Histoplasma 
capsulatum in human monocytes. When used in a murine model of histoplasmosis, a 
dose of 120 mg/kg of chloroquine protected the mice against lethal infection with 
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Histoplasma capsulatum [80]. The mechanism of action of chloroquine and 
quinacrine against Histoplasma capsulatum was found to be iron deprivation [80]. 
Mefloquine was studied against Candida albicans, Candida glabrata and Candida 
krusei and Cryptococcus neoformans, displaying good in vitro activity comparable 
with that of amphotericin B. MICs ranged between 0.8 and 3.5 µg/ml [81]. These 
drugs are concentrated in the brain and other organs. 
Pentamidine is a member of the aromatic diamine class, with activity against a 
number of different bacteria and protozoa [82, 83]. In vitro antifungal activity is 
exhibited against yeasts, including Candida albicans, Saccharomyces cerevisiae, 
Cryptococcus neoformans, Aspergillus niger, Aspergillus terreus, Aspergillus 
nidulans and Aspergillus ustus [54, 84, 85, 86]. Analogues of pentamidine were 
active in vitro against Candida spp., including fluconazole-resistant strains of Candida 
albicans, Candida krusei and Candida glabrata, and in moulds, including Aspergillus 
fumigatus, Aspergillus flavus and Fusarium [87]. Pentamidine combined with 
ketoconazole displayed synergistic interaction [88]. HIV-positive patients under 
prophylaxis with nebulized pentamidine had lower concentrations of Candida 
intraorally than those who did not receive this prophylaxis, indicating that the drug is 
also active against Candida in vivo [89]. 
In Vitro Data Drug in combinationDrug Microorganism
(n) MIC MFC Drug Result
Reference
AMB: Amphotericin B; KTZ: Ketoconazole; ITZ: Itraconazole; SYN: Synergistic effect;  
MIC, minimal inhibitory concentration. MFC, minimal fungicida l concentration.   
C. neoformans 
(11)
10µg/ml 12.5->100
µg/ml
[84]
C. neoformans 
(5)
3.12µg/ml 6.25µg/ml [87]
KTZ SYNCandida spp (11) 1µg/ml
ITZ SYN
[88]
Candida spp (8) 0.78µg/ml 1.56µg/ml
Aspergillus spp 
(2)
0.19µg/ml 3.12µg/ml
Aspergillus spp 
(70)
13.2µg/ml >128µg/ml
Fusarium (1) 0.39µg/ml 0.39µg/ml
Pentamidine
Scedosporium 
prolificans (30)
57µg/ml 165µg/ml AMB SYN
[87]
[54]
[92]
Chloroquine C. neoformans 
(5)
30 µM ≥100 µM
Quinacrine 1 µM 5 µM
[79]
Candida spp (4)Mefloquine
C. neoformans 
(2)
0.8-3.1µg/ml [81]
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Disseminated infection by Scedosporium prolificans most commonly occurs in 
neutropenic patients with haematologic malignancies. It is a rapidly fatal infection 
characterized by fever and multiorgan failure. Many patients have been treated with 
amphotericin B and, occasionally, with other antifungal agents, though often with 
unsuccessful outcomes [90, 91]. Synergistic in vitro interaction was found when 
amphotericin B was combined with pentamidine against a collection of 30 clinical 
isolates of Scedosporium prolificans [92]. 
Albendazole was studied in order to verify its potential antifungal activity. Good 
activity was observed in vitro against Candida spp. and Cryptococcus neoformans, 
but the drug was inactive in an animal model. This might be due to the fact that the 
principal metabolite, albendazole sulfoxide, is inactive against yeasts [93]. 
 
Other Compounds 
Cecoprin A is a lytic peptide that causes cell lysis by inducing large pores in bacterial 
cell membranes. The in vitro activity of this compound was studied against 
germinated and ungerminated conidia of Aspergillus fumigatus, Aspergillus flavus, 
Aspergillus niger, F. oxysporum and F. monoliforme. The fungicidal activity was 
validated using two in vitro techniques based on a microwell assay and fluorescent 
microscopy. The compound was lethal within 30 minutes against germinating 
Aspergillus spp. and against nongerminating and germinating Fusarium spp. at 
concentrations as low as 2 µg/ml. Cecoprin A can be used safely in animals and 
might be useful as a topical agent in keratitis caused by these fungi [94]. 
Del Poeta et al. [95] described the antifungal activity of 67 compounds such as 
carbazoles and furans that exhibited activities equal to or greater than those of 
fluconazole and amphotericin B. These classes of compounds were not only 
inhibitory but also exhibited in vitro fungicidal activity against Candida albicans, 
Candida krusei, Candida lusitaneae, Candida parapsilosis, Candida tropicalis, 
Candida glabrata, Cryptococcus neoformans, Aspergillus fumigatus, Aspergillus 
flavus, Fusarium and Rhizopus. 
Diazeniumdiolates are stable agents capable of releasing nitric oxide in an aqueous 
environment or in response to local pH. In combination with azoles, synergistic 
interaction was displayed in vitro against Candida spp., including those resistant to 
azoles [96]. 
Patients with cystic fibrosis and chronic obstructive pulmonary disease are at risk for 
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colonization of the respiratory tract with Aspergillus. Aerosolized mucolytic drugs 
such as N-acetylcysteine are commonly used to solubilize mucus plugs in the lungs. 
De Lucca et al. [97] demonstrated in vitro activity of N-acetylcysteine and L-cysteine 
against Aspergillus spp. and Fusarium. N-acetylcysteine was more potent than L-
cysteine in inhibiting the conidial germination of these moulds. The mechanism of 
action is not well understood, but cysteine is believed to reduce conidial wall 
permeability to nutrients, thereby affecting germination. The concentration of these 
compounds in aerosolized form equals or exceeds the concentration required for 
antifungal activity, indicating the potential for prevention of invasive fungal infection in 
immunocompromised patients. 
 
Other agents that have synergistic interaction in vitro with the azoles against Candida 
and Cryptococcus are cholesterol-lowering agents such as fluvastatin, pravastatin, 
lovastatin and simvastatin. Fluvastatin in combination with fluconazole or itraconazole 
displayed synergistic fungicidal interaction in vitro against Candida albicans, Candida 
tropicalis, and Cryptococcus neoformans. The combination of these compounds plus 
amphotericin B showed additive interaction [98]. However, azoles and cholesterol-
lowering agents significantly inhibit the liver enzymes CYP2C9 and CYP3A4 [99]. 
Several case reports indicate that concomitant therapy predisposes patients to 
myositis and rhabdomyolysis [100, 101], thereby limiting concomitant systemic 
In Vitro Data Drug in combinationDrug Microorganism
(n) MIC MFC Drug Result
Reference
AMB: Amphotericin B; FCZ: Fluconazole; KTZ: Ketoconazole; MCZ: Miconazole; ITZ: Itraconazole; SYN: Synergistic effect; 
ADD: Additive affect; IDD: Indifferent effect.  
MIC, minimal inhibitory concentration. MFC, minimal fungicida l concentration.   
1-3µg/ml FCZ SYN [105]
Nikkomycin SYN
AMB ADD
10-100µg/ml
Econazol SYN
[104]
MCZ SYN
Ibuprofen Candida spp 
(18)
1024µg/ml
FCZ SYN
[103]
>2µg/ml FCZ IDD
FCZ SYN
C. albicans (8)
16-
>128µg/ml ITZ SYN
FCZ ADD
Fluvastatin
C. neoformans 
(3)
>128µg/ml
ITZ ADD
[102]
[98]
KTZ SYN
FCZ SYN
Nitric Oxide Candida spp
(20)
0.38-1µg/ml
ITZ SYN
[96]
Aspergillus spp 
(3)
25 µg/ml 99µg/ml Cecoprin A
Fusarium (2) 6µg/ml
[94]
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administration. The combination might be benefical as topical therapy for patients 
with chronic recurrent oropharyngeal candidosis or other mucocutaneous infections 
caused by Candida [98, 102]. 
Ibuprofen, a nonsteroidal anti-inflammatory drug, exhibited weak antifungal activity 
alone and in combination with fluconazole, miconazole and nikkomycin z, using 
different in vitro techniques [103, 104, 105]. There are no clinical data that support 
this in vitro observation. In contrast, the combination fluconazole and ibuprofen was 
less effective than the drugs alone in a murine model of disseminated histoplasmosis 
[106]. 
 
Conclusion 
Given the increasing incidence of invasive fungal infection and the limited efficacy of 
currently available antifungal agents, new approaches are needed. A broad spectrum 
of drugs and natural products  produced by microorganisms might be investigated for 
their antifungal activity. Review of the literature shows that a considerable number of 
drugs that are used in clinical practice for indications other than treatment of 
infectious diseases exhibit antifungal activity.  However, the currently published data 
are on in vitro activity and efficacy in animals. There is very limited clinical data that 
indicates clinically relevant activity of non-antifungal compounds within patients. In 
vitro techniques that allow detailed analysis of drug interaction against moulds have 
recently been developed and are used to determine the nature of the interaction. In 
addition animal studies that take pharmacodynamics into account need to be 
performed. Based on these data new approaches to the management of invasive 
fungal infection can be designed. 
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Abstract 
 
The susceptibilities of 70 strains of Aspergillus species was tested against seven 
different sulfa drugs and pentamidine by a microdilution method with RPMI 1640 and 
yeast nitrogen base media.  Sulfamethoxazole, sulfadiazine, and pentamidine were 
active in vitro. The MICs obtained with RPMI 1640 were significantly higher than 
those with yeast nitrogen base. More studies are needed to further elucidate the 
action of these drugs. 
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Introduction 
Invasive aspergillosis is now one of the most common invasive fungal infections in 
immunocompromised patients and carries high mortality rates (6). Invasive 
aspergillosis is a rare complication of end-stage AIDS despite the 
immunocompromised status of the host. Although invasive aspergillosis in AIDS is 
associated with neutropenia and corticosteroid therapy, other factors might contribute 
to the low incidence. Sulfonamides, especially trimethoprim-sulfamethoxazole (SXT) 
are antimicrobial agents frequently  employed for prophylaxis in AIDS patients to 
prevent Pneumocystis carinii pneumonia. Sulfa drugs are active against 
Paracoccidioides brasiliensis (16,17) and  pentamidine (PNT) has some activity 
against  yeast  (2, 5,13).  We have recently shown that sulfamethoxazole (SMX) is 
active in vitro against A. fumigatus and therefore might help to prevent invasive 
aspergillosis in AIDS patients receiving SXT prophylaxis (1). The aim of this study 
was to further evaluate the in vitro activity of seven different sulfa compounds and 
PNT against  Aspergillus isolates comprising of six different species in two different 
media. 
 
Materials and Methods 
Seventy clinical isolates of Aspergillus were tested: 20 isolates of A. fumigatus and 
10 isolates each of the following species: A. flavus,  A. niger, A. nidulans, A. ustus 
and A. terreus. Isolates were passaged twice in PDA at an interval of 5 to 7 days at 
37°C. All isolates were tested in duplicate on two different days. A broth microdilution 
method was performed according to National Committee for Clinical Laboratory 
Standards (NCCLS) guidelines (M38-P) (14). The drugs used in this study were: 
trimethoprim (TMP), SMX, SXT, pyrimethamine (PMT), dapsone (DAP), 
sulfamethizole (SMT), sulfisoxazole (SSX), sulfadiazine (SDZ), sulfa-
methoxypyridazine (SMP) and PNT. All drugs were obtained as standard powders 
from Sigma-Aldrich Chemie GmbH, Steinheim, Germany.  The final concentrations of 
the drugs ranged from 16 to 0.01  µg/ml for TMP and DAP, 320 to 0.31 µg/ml for 
SMX, and 16/320 to  0.01/0.31 µg/ml for SXT (1:20dilution ratio), 4 to 0.004 µg/ml for 
PMT, 500 to 0.4 µg/ml for SMT, 128 to 0.12 µg/ml for PNT,  400 to 0.3  µg/ml for 
SSX, SDZ and SMP. Dimethyl sulfoxide (DMSO) was used to dissolve all drugs 
except for PNT, which was dissolved in water. 
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The drug dilutions were made in RPMI 1640 medium (with L-glutamine, without 
bicarbonate) (GIBCO BRL, Life Technologies, Woerden, The Netherlands) and in 
yeast nitrogen base (YNB) (DIFCO Laboratories, Sparks, USA) and were  prepared 
according to the manufacturer’s instructions. Both media were  buffered to pH 7.0 
with 0.165 morpholinepropanesulfonic acid (MOPS) (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany).  
The tests were performed in 96-well flat-bottom microtitration plates (Corning 
Incorporated, NY, USA).  Conidia were collected with a cotton stick and suspended in 
sterile water. After the heavy particles were allowed to settle, the turbidities of the 
supernatants were measured spectrophotometrically (Spectronic 20D; Milton Roy, 
Rochester, N.Y., USA) at 530 nm, and transmission was adjusted to 80 to 82% and 
diluted to obtain a final inoculum of 0.5 x 104 to 5 x 104 CFU/ml. The inoculum size 
was verified by determination of the number of viable CFU per ml after plating serial 
dilutions of the inoculum onto Sabouraud dextrose agar (SDA).  
Each suspension was diluted 1:50 in RPMI 1640 and in YNB to obtain two times the 
final inoculum.  
After agitation, the plates were incubated at 35°C for  48 h. The visual MIC was 
defined as the lowest concentration showing prominent growth inhibition (MIC - 2, 
approximately ≥50% inhibition).  For spectrophotometric endpoint determination,  the 
optical density (OD) was measured with a spectrophotometer (MS2 reader, Titertek-
plus; ICN Biomedical Ltd., Basingstoke, United Kingdom) at 405 nm. The OD of the 
blank, a microtitration plate  to which a conidium-free inoculum had been added and 
incubated, was subtracted from the OD values. The percentage of growth for each 
well was calculated by comparing the OD of the well which that of the drug-free 
control. The in vitro fungicidal activity (minimal fungicidal concentration [MFC]) of 
each agent was determined by streaking 100 µl from each well that showed complete 
inhibition onto SDA plates. The plates were incubated at 35°C. The MFC was defined 
as the lowest drug concentration at which growth of less than one colony was 
observed, which corresponds with 99.9 % killing. 
The results were analysed by the Mann-Whitney Test and differences were 
considered statistical significant at P < 0.05 . 
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Results and Discussion 
The inoculum size was checked by enumeration of 
colonies per milliliter of serial dilutions  on SDA plates. 
These cultures showed that the final inoculum varied 
between 1 x 104 and 4 x 104 CFU/ml, which is within the 
recommended range (14).The MICs for all the drugs in 
both media tested are summarized in Table 1. All  
sulfonamides and PNT showed higher MICs in RPMI 
medium than in YNB medium (P <0.0001). The lowest 
MICs in YNB were obtained for  SMX, SXT, SMP, SDZ 
and PNT.   
SSX and SMT were inactive  against most of the strains. 
TMP, PMT and DAP were inactive against all the 
isolates.  SMX, SXT, SMT, SMP and SDZ  were active 
against the 20 A. fumigatus isolates (Table 2). In vitro, 
lower MIC values were observed for A. niger  for SMX, 
SXT, SDZ, SMP and PNT and for SMX, SXT, SMT, SMP, 
SDZ and PNT against A. nidulans. SXT and PNT showed 
the highest activity for this fungus. All the drugs were less 
active against A. ustus and A. terreus  except for  PNT.  
No statistical significant difference in the MICs between 
SMX alone or in combination with TMP (SXT) was found 
(P>0.05).  
Considering the MIC/MFC ratios, fungistatic activity was 
observed for all tested drugs, except for PNT, which was 
fungicidal for A. nidulans. Nevertheless, despite the low 
MIC and the volume plated for MFC determination, carry 
over of drug could be present. More studies with other 
methods are need in order to confirm this observation.  
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Sulfonamides act as competitive antagonist of p-
aminobenzoic acid (PABA), which is an integral 
component of the structure of folic acid. The result of 
decreased folic acid synthesis is a decrease in  
nucleotides, with subsequent inhibition of growth (21). 
Sulfonamides exhibit in vitro activity against a broad 
spectrum of gram-positive and gram-negative bacteria, 
parasites, and fungi (21), and  the combination SXT acts 
synergistically  against Paracoccidioides brasiliensis (3, 
9,16,17,20). The in vitro antimicrobial activity of 
sulfonamides is strongly influenced by the composition of 
the test medium, since the presence of PABA and folic 
acid in the medium inhibits their activity (21). RPMI is the 
standard medium recommended by the NCCLS (14) for 
in vitro susceptibility testing of yeast and molds, but 
contains 4 times more PABA than YNB (according to 
manufacturer’s manual). Consequently, MICs were found 
to be higher with RPMI than those obtained with YNB, 
with the same inocula. Furthermore, RPMI poorly 
supports  the growth of Aspergillus  species compared 
with the richer medium, YNB (12).   
These factors probably contribute to the discrepancies 
found between the two media. There are no  MIC 
endpoints for sulfa drugs against molds but in previous 
studies MIC-2 was used as endpoint against P.  
brasiliensis  and C. albicans (4,16,17). Therefore, we 
chose the same endpoint in this study. The 
concentrations of sulfa drugs in plasma in general, are 
between 100 and 200 µg/ml. For SMX, levels of 40 to160 
µg/ml are generally found (8,21), which is near or above 
the MICs found for A. fumigatus, A. flavus, A. niger, A. 
nidulans.  
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The mechanism of action for PNT is unknown, and the compound displays multiple 
effects in extracts of P. carinii (19). In vitro, PNT is active against a number of 
different protozoa and fungi (10,11,13,19). In vivo, patients who received aerosolised 
PNT had less oral colonization with Candida species (15). Patients who receive 4 
mg/kg of body weight daily by slow intravenous infusion can achieve a concentration 
of 0.5 to 3.2 µg/ml in blood (5). However, much higher levels are found in tissues, 
with concentrations up to 56 µg/g in lung, 300 µg/g in liver, and 123 µg/g in the  
kidney (5). When achievable drug levels are related to MIC values, A. nidulans, A. 
niger,  A. ustus and  A. terreus have MICs below the plasma drug concentration and 
tissue drug levels. These species are often clinically refractory to standard treatment 
with amphotericin B (7, 18) and therefore PNT might be useful as  treatment for 
infections due to these Aspergillus species.  
More studies with different media and animal models, and clinical studies are 
necessary  to elucidate the potential of these drugs for the treatment of  Aspergillus 
infections. 
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Summary 
Because invasive aspergillosis is encountered relatively infrequently in HIV - infected 
patients, we hypothised that prophylaxis for Pneumocystis carinii pneumonia (PCP) 
might also prevent invasive Aspergillus infections. The literature was reviewed for 
cases of invasive aspergillosis in HIV-infected patients that developed during 
prophylaxis for PCP. Among 18 patients described, 4 had received the standard 
regimen of trimethoprim-sulfamethoxazole (TMP-SMZ). SMZ was found to be active 
in vitro against Aspergillus fumigatus as opposed to TMP, pentamidine and dapsone. 
Since the MIC of 19 of 20 A. fumigatus isolates were in the range of SMZ blood 
levels, PCP prophylaxis with TMP-SMZ could prevent invasive aspergillosis in HIV-
infected patients. 
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Invasive aspergillosis is a significant cause of morbidity and death in 
immunocompromised patients, including those with AIDS. Although the incidence of 
this infection is low, the risk is increased in those with low counts of CD4+T 
lymphocytes, neutropenia and during corticosteroid treatment. Sulfonamides, 
especially trimethoprim-sulfamethoxazole (TMP-SMZ) are antimicrobial agents that 
have frequently been employed to prevent Pneumocystis carinii pneumonia (PCP), 
toxoplasmosis encephalitis and bacterial respiratory infections in HIV-infected 
patients. During prophylaxis with TMP-SMZ 13.9% of patients develop adverse 
events that necessitate discontinuation [1], and alternative regimens such as 
dapsone, or aerosolized pentamidine are considered [2]. Since Pneumocystis is now 
considered to belong to the fungal kingdom, we investigated whether these drugs 
were active against Aspergillus spp. This is of relevance because patients at risk of 
PCP are often also at risk for developing invasive aspergillosis. The literature was 
reviewed for cases of invasive aspergillosis in HIV-infected persons or those with 
AIDS, which had also documented the drug that was used to prevent PCP. Only 18 
cases have been described in the literature that met these criteria. Mylonakis et al. 
described two cases of invasive aspergillosis caused by A. fumigatus undergoing 
dapsone prophylaxis [3]; Pursell et al. described five cases undergoing TMP-SMZ 
prophylaxis in which two were due to A. fumigatus and one to A. flavus [4]. Among 
these, 14 patients had received dapsone or pentamidine prophylaxis and four TMP-
SMZ. The largest series was published by Denning et al. where 13 patients with 
AIDS were described who developed invasive aspergillosis, of who 12 (92%) had 
received PCP-prophylaxis with pentamidine [5]. Taking into account the proportion of 
patients that received either TMP-SMZ or alternative regimens, the probability of 
developing invasive aspergillosis in patients who received alternative PCP 
prophylaxis is much higher than for those on prophylaxis with TMP-SMZ (RR 21.5). 
This suggests that TMP-SMZ might show activity against Aspergillus as opposed to 
pentamidine or dapsone. Therefore, the in vitro activity of TMP-SMZ, dapsone and 
pentamidine was determined against a collection of 20 clinical A. fumigatus isolates 
and 10 A. flavus isolates. The in vitro activity was determined according to the 
proposed guidelines of the NCCLS for the susceptibility testing of conidium-forming 
fungi (M38-P) using microdilution format [6]. The minimal inhibitory concentration 
(MIC) was read at 50% inhibition of growth compared with that of the drug-free well 
(Table 1). TMP-SMZ was active in vitro against A. fumigatus (geometric mean MIC 
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54.6 µg/ml, range 40 - 160  µg/ml), and TMP alone was inactive (geometric mean 
MIC > 8 µg/ml). The antifungal activity of TMP-SMZ appeared to be fungistatic. 
Dapsone and pentamidine were inactive in vitro against all Aspergillus isolates at 
therapeutic concentrations. The recommended dose of TMP-SMZ for the prevention 
of PCP pneumonia in patients with HIV infection is 160/800 q.d. [2], which results in 
peak blood levels of SMZ that range between 40 and 60 µg/ml. These blood levels 
are equal to or above the MIC of 19 of 20 A. fumigatus isolates, but too low to inhibit 
any of the A. flavus isolates. 
The results of literature review and the in vitro findings suggest that PCP prophylaxis 
with TMP-SMZ may prevent invasive aspergillosis in HIV-infected patients when 
caused by A. fumigatus, although the concentration achieved in the blood are 
marginal to effectively prevent the infection. Further studies are required to confirm 
this observation and to establish whether sulfonamides also show activity against 
other fungal pathogens such as Cryptococcus and Histoplasma. 
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Abstract 
The in vitro activity of eight antipsychotic drugs (chlorpromazine [CPZ], 
trifluopherazine [TFP], fluphenazine [FNP], flunarizine [FNZ], fluspirilen [FPL], 
cinnarizine [CNZ], chloprothixene [CPT] and thiothixene [TTX]) was evaluated 
against 202 isolates including 72 yeasts (22-Candida albicans, 10-C. krusei, 
10-C. glabrata and 30-Cr. neoformans) and 130 molds (30-zygomycetes, 20-
Aspergillus. fumigatus, 10-A. flavus, 10-A. niger, 10-A.ustus, 10-A. terreus, 
10-Scedosporium apiospermun and 30-S. prolificans). These drugs are 
known to interact with the Ca+2 metabolism of eukaryotic cells. CPZ, TFP, 
FNP and CPT inhibited the growth of all species tested at concentrations 
ranging from: 21.1 to 97 mg/L, 16 to 64 mg/L, 25 to 84 mg/L and 16 to 64 
mg/L, respectivelly.  No in vitro activity was observed for TTX, CNZ and FPL 
against all isolates tested. Considering the MIC/MFC ratios, fungistatic activity 
was observed for all the antipsychotic drugs that were active against the 
strains tested.  
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Introduction 
Fungal infections have increased dramatically during the last two decades 
due to several factors such as increased number of patients that undergo  
immunosuppressive treatment, long term catheterization, broad spectrum 
antibiotic use, diabetic ketoacidosis, neutropenia, patients receiving 
corticosteroids and longer survival of immunologically compromised 
individuals.  
However, despite antifungal therapy, mortality in patients with invasive fungal 
infection remains very high and clearly new therapeutic approaches are 
needed. Although resistance to antifungal azoles plays a limited role in the 
low response rates, studies of the mechanisms of resistance in yeasts and 
molds have contributed to an increased insight in drug-fungus interaction. 
Resistance mechanisms include changes in the cellular content of the azole 
(altered uptake or efflux mechanisms), mutations in sterol desaturation during 
the ergosterol biosynthesis, and mutations in or elevated levels of 14α-
demethylase1,2. The recent discovery of drug-efflux-mediated resistance 
mechanisms in yeasts and molds open new therapeutic concepts. 
Although other promising targets are being explored by pharmaceutical 
industries 3, the therapeutic arsenal currently available in clinical practice is 
mainly limited to members of the classes of the polyenes and azoles. 
Moreover, the development of antifungal drug resistance, toxicities of existing 
therapeutic regimens and the high cost of new drug delivery formulations, 
necessitate the development of drugs with alternative modes of action against 
molds and yeasts. 
Phenothiazine compounds and thiothixene, currently in use as antipsychotic 
agents, have gained renewed interest as antifungal drugs mainly because of 
their action on calmodulin 4.  
The aim of the present study was to determine the in vitro activity of seven 
antipsychotic drugs against 202 yeast and mold isolates with variable 
resistance to conventional antifungal agents.  
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Materials and methods 
Test isolates. 202 clinical yeast and mold isolates were tested. A total of 22 
were clinical Candida albicans isolates, kindly provided by Laura Rodero 
(Departamento de Micología, INEI, ANLIS Dr. Carlos G. Malbrán, Argentina).   
Five strains were susceptible in vitro to fluconazole (MICs of 8 mg/L), 15 were 
susceptible-dose-dependent (10 with MICs of 16 mg/L and 5 with MICs of 32 
mg/L) and 2 were resistant (with MICs of >128 mg/L). Five strains were 
susceptible to itraconazole (range between 0.03 to 0.12 mg/L), 9 susceptible 
dose dependent (MIC range between 0.25 to 0.5 mg/L) and 8 resistant (with 
MICs > 1 mg/L), according to the NCCLS breakpoint  definitions 5. 
All other isolates were part of the private collection of the Department of 
Medical Microbiology, University Medical Center Nijmegen, Nijmegen, the 
Netherlands. The following isolates were included: C. glabrata (10), C. krusei 
(10), Cryptococcus neoformans (30), Rhizopus oryzae (7), R. microsporus (7) 
Absidia corymbifera (10), Mucor circinelloides (1), M. hiemalis (3), 
Rhizomucor miehei (1), R. pusillus (1), Aspergillus fumigatus (20) (including 7 
itraconazole resistant [ITZ-R] isolates [V09-18, V09-19, AZN5241, AZN5242, 
AZN7720, AZN7722, A.ZG7] 6), A. flavus (10), A. niger (10), A. ustus (10), A. 
terreus (10), Scedosporium apiospermum (10) and S. prolificans (30). C. 
parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) were used for quality 
control in all experiments.  
Antifungal susceptibility testing of yeasts. The inoculum for the yeasts and 
quality controls were prepared from 1- to 2-day-old colonies, which were 
suspended in saline, and the transmittance was adjusted to 75 to 77% at 530 
nm. For Candida, the blastoconidial suspensions were then diluted 1:1,000 to 
obtain double the final inoculum, which ranged from 0.5 x 103 to 2.5 x 103 
CFU/ml. The plates were incubated at 35°C for 48 h. For Cr. neoformans the 
blastoconidial suspensions were diluted 1:10 with sterile distilled water. The 
final inoculum contained 0.5 × 105 to 2.5 × 105 CFU/ml. The plates were 
incubated at 35°C for 48 h with shaking 7. 
Antifungal susceptibility testing of molds. The mold isolates were 
passaged twice at an interval of 5 to 7 days at 30°C by first subculturing them 
onto Sabouraud glucose agar (SGA) and then onto Takashio agar in order to 
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obtain adequate sporulation. Conidia or spores were collected with a cotton 
swab and suspended in sterile saline with 0.05% Tween 20. After the heavy 
particles were allowed to settle, the turbidities of the supernatants were 
measured spectrophotometrically (Spectronic 20D; Milton Roy, Rochester, 
N.Y.) at 530 nm, and transmittance was adjusted to 80 to 82% for Aspergillus,  
68 to 70% for S. apiospermun and S. prolificans. Thus  the inoculum 
corresponded to 0.5 x 106 to 4.5 x 106 CFU/ml and was then diluted into 
RPMI-1640 to a concentration of 0.5 x 104 to 5 x104 conidia/mL . 
For zygomycetes, spore suspensions were counted with a hematocytometer 
and then diluted with RPMI-1640 to a concentration of 2 x 104 spores/mL. 
Inoculum sizes were checked by quantitative colony counts on SGA. The 
inoculum size was confirmed by plating serial dilutions onto SGA plates. The 
plates were incubated at 35°C for 24 h for zygomycetes, 48 h for Aspergillus 
and 72 h for Scedosporium spp .  
The blastononidia, conidia and spores of the isolates were obtained from 
fresh cultures each time.  
Media for yeast and molds. RPMI-1640 medium with L-glutamine, without 
bicarbonate (GIBCO BRL, Life Technologies, Woerden, the Netherlands) 
buffered to pH 7.0 with morpholinepropanesulfonic acid (MOPS) (Merck, 
Darmstadt, Germany),  supplemented with 18 g of glucose per liter to reach a 
final concentration of 2% (RPMI) was used for yeast and without glucose 
supplementation for moulds. All media were filter sterilized by passage 
through a 0.22-µm-pore-size filter system. 
Antifungal and antipsychotic drugs. The antifungal drugs used in this study 
were amphotericin B (AMB) (Bristol-Myer Squibb, Woerden, the Netherlands), 
fluconazole (FCZ) (Pfizer, Capelle aan den IJssel, the Netherlands) and 
itraconazole (ITZ) (Janssen Research Foundation, Beerse, Belgium). The 
antipsychotic drugs (fig 1) included chlorpromazine (CPZ), cinnarizine (CNZ), 
trifluopherazine (TFP), fluphenazine (FPN), flunarizine (FNZ), fluspirilene 
(FLP), chlorprothixene (CPT), thiothixene (TTX) and were obtained from 
Sigma-Aldrich Chemie GmbH (Steinheim, Germany).  AMB, ITZ, CNZ, FNZ, 
CPT and TTX were dissolved  in dimethylsulfoxide (DMSO) and FCZ, FNP, 
CPZ and TFP were dissolved in water to make stock solutions which were 
held at –70ºC until use.   
Activity of antipsycotic drugs against yeast and molds 
 63
The tests were performed in 96-well flat-bottom microtitration plates (Corning, 
Inc., New York, N.Y.). Serial twofold dilutions of each antifungal and 
antipsychotic agent were prepared following NCCLS guidelines according to 
the documents M27-A2 for yeast and M38A for moulds5,8. The final 
concentrations of the drugs ranged from 0.01 to 16 mg/L for AMB and ITZ,  
from 0.12 to 128 mg/L for FCZ,  from 0.5 to 512 mg/L for CPZ, TPZ, FNP, 
TTX, CPT and from 0.03 to 32 mg/L for FPL. The range of the concentration 
always included the drug levels achievable in humans. 
All isolates were tested two times on 2 different days. 
 
MIC endpoints. A numerical score was given as follows: 4, no reduction in 
growth; 3, slight reduction in growth or approximately 75% of the growth 
control (compared with drug-free medium); 2, prominent reduction of growth 
or approximately 50% of the growth control; 1, slight growth or approximately 
25% of growth control; and 0, optically clear well  or absence of growth.  
Thiothi xene
Trif luopherazine Fluphenazi ne
Chlopromazine Chloprothixene
Cinnarizi ne
Fig 1. Molecular structures of antipsychotic drugs
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For spectrophotometric endpoint determination, the optical density (OD) was 
measured with a spectrophotometer (MS2 reader, Titertek-Plus; ICN 
Biomedical, Ltd., Basingstoke, United Kingdom) at 405 nm and 450 nm for 
moulds and yeasts respectively. The OD of the blank, a microtitration plate to 
which a conidium/spore-free inoculum had been added and incubated, was 
subtracted from the measured OD values. The percentage of growth for each 
well was calculated by comparing the OD of the well with that of the drug-free 
control. The MIC for FCZ and ITZ was defined as the lowest concentration 
showing prominent growth inhibition (MIC-2) against Candida and 
Cryptococcus.  The MIC for ITZ and for all other drugs against all moulds was 
defined as the lowest concentration showing no growth (MIC-0) according for 
NCCLS guidelines (M27-A2 and M38A) 5,8 .   
The in vitro fungicidal activity (minimal fungicidal concentration [MFC]) of each 
agent was determined by streaking 100 µl from each well that showed 
complete inhibition of growth (95% inhibition or an optically clear well) onto 
SGA plates. The plates were then incubated at 35°C for 72 h. The MFC was 
defined as the lowest drug concentration at which there was either no growth 
or only a single colony, which corresponds with 99.9% killing. The drug was 
considered fungicidal if the ratio of MFC to MIC did not exceed a value of 4. If 
the ratio was greater than 4, the in vitro activity was considered to be 
fungistatic 9 .  
 
Results 
The MICs of AMB, FCZ and ITZ based on MIC-2 for C. krusei (ATCC 6258) 
were 1, 32 and 0.5 mg/L and for C. parapsilosis (ATCC 22019) were 1, 2 and 
0.12 mg/L, respectively, which is inside the reference range for quality control 
strains. For the other drugs no reference range is established. Nevertheless 
the MICs of  CPZ, TFP, CTT, and FNP for C. krusei (ATCC 6258) were 16, 
32, 64 and 64 mg/L and for C. parapsilosis (ATCC 22019) were 8, 16, 32, and 
64 mg/L respectively. TTX, CNZ and FPL appeared to be not active in vitro 
against these quality control isolates.  
The MICs the drugs tested are summarized in tables 1 to 4. TFP, CPZ, CPT 
and FNP showed moderate in vitro activity against C. albicans, C. krusei and 
C. glabrata with low and high MICs of FCZ and ITZ(Table 1). 
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In addition low MICs were found for AMB and ITZ against zygomycetes. 
Moderate MICs were found also for TFP, CPZ, CPT and FNP (Table 2). 
Among the A. fumigatus isolates, 7 were resistant to ITZ (MIC >16 mg/l) 
compared with a MIC of 0.5 mg/L for the ITZ-S strains. Despite this divergent 
susceptibility to ITZ the MIC for TFP, CPZ, CPT and FNP were 32, 64, 64 and 
64 mg/L, respectively, with no more than 1 dilution difference in the MIC 
between ITZ-S and ITZ-R isolates (Table 3). 
Table 1. Susceptibility in vitro of Candida spp. and Cryptococcus neoformans to 
antifungal and antipsychotic drugs 
 
MIC (mg/L) Strain (no. of isolates) 
and drug GM MIC50 MIC90 Range 
C. albicans (20)     
Amphotericin B 0.75 1 1 0.25-1 
Fluconazole 20.5 16 32 8->128 
Itraconazole 0.58 0.25 32 0.03->16 
Chlorpromazine 68.5 64 128 32-128 
Trifluopherazine 36.7 32 64 16-64 
Thiothixene 362 512 512 128->512 
Chlorprothixene 48.5 64 128 4-128 
Fluphenazine 84.4 64 128 64-128 
C. krusei (10)     
Amphotericin B 0.87 1 1 0.5-2 
Fluconazole 27.8 32 32 16-32 
Itraconazole 0.38 0.5 0.5 0.25-0.5 
Chlorpromazine 21.1 16 32 16-32 
Trifluopherazine 45.2 32 64 32-64 
Thiothixene 207.9 256 256 128-512 
Chlorprothixene 64 64 128 32-128 
Fluphenazine 64 64 64 64 
C. glabrata (10)     
Amphotericin B 0.71 1 1 0.5-1 
Fluconazole 10.5 16 64 0.25->128 
Itraconazole 1.7 2 8 0.5->16 
Chlorpromazine 97 128 128 16-128 
Trifluopherazine 48.5 64 64 32-64 
Thiothixene 207.9 128 512 128-512 
Chlorprothixene 48.5 32 64 32-128 
Fluphenazine 64 64 128 16-128 
C. neoformans (30)     
Amphotericin B 0.64 0.5 1 0.25-1 
Fluconazole 1.85 2 4 0.25-8 
Itraconazole 0.05 0.06 0.12 0.01-0.25 
Chlorpromazine 27.9 32 32 16-32 
Trifluopherazine 16 16 16 8-16 
Thiothixene 143.6 128 256 128-256 
Chlorprothixene 28.06 32 64 16-128 
Fluphenazine 25.4 32 32 16-128 
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For A. flavus and A. terreus the highest MICs were observed for AMB (>1 
mg/L). In addition for these species MICs were observed for the antipsychotic 
drugs with a range from 32 to 64 mg/L (Table 3). AMB and ITZ had low 
activity against S. apiospermum and S. prolificans with MICs90 of 4  mg/L for 
S. apiospermum and 4 to >16 mg/L for S. prolificans. Also MICs were 
obtained for TFP,CPZ, and CPT against both species (Table 4). CPZ, TFP, 
CPT and FNP were active against all isolates tested (Fig 1) with different 
patterns depending on the genera or species tested. For CPZ, TFP, FNP and 
CPT the range of the mean MICs ranged between 21.1 to 97 mg/L, 16 and 64 
mg/L, 25 and 84.4 mg/L and 16 and 64 mg/L, respectively, for all strains 
tested.   
 
 
 
 
Table 2 Susceptibility in vitro of Zygomycetes to antifungal and antipsychotic drugs
MIC (mg/L)Strain (no. of isolates) 
and drug GM MIC50 MIC90 Range
Absidia spp (10)
Amphotericin B 0.09 0.06 0.12 0.06-0.25
Fluconazole ND ND ND ND
Itraconazole 0.44 0.5 0.5 0.25-1
Chlorpromazine 59.7 64 64 32-64
Trifluopherazine 34.3 32 32 32-64
Thiothixene 388 512 512 256-512
Chlorprothixene 22.6 32 32 16-32
Fluphenazine 64 64 64 64
Rhizopus spp (14)
Amphotericin B 0.45 1 1 0.06-1
Fluconazole ND ND ND ND
Itraconazole 1.64 0.5 16 0.5-16
Chlorpromazine 32 32 32 32
Trifluopherazine 16 16 16 16
Thiothixene 256 256 512 128-512
Chlorprothixene 28.9 32 64 16-64
Fluphenazine 32 32 32 16-64
Mucor spp  (3)
Amphotericin B 0.09 ND ND 0.03-0.25
Fluconazole ND ND ND ND
Itraconazole 7.1 ND ND 1->16
Chlorpromazine 32 32 32 32
Trifluopherazine 19.03 ND ND 16-32
Thiothixene 181.02 ND ND 128-256
Chlorprothixene 22.6 ND ND 16-32
Fluphenazine 32 32 32 32
Rhizomucor (2)
Amphotericin B 0.06 ND ND 0.06
Fluconazole ND ND ND ND
Itraconazole 0.5 ND ND 0.25-1
Chlorpromazine 32 ND ND 32
Trifluopherazine 16 ND ND 16
Thiothixene 256 ND ND 256
Chlorprothixene 32 ND ND 16-64
Fluphenazine 32 ND ND 16-64
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In vitro, lower MICs were observed for C. krusei (geometric mean of 21.1 
mg/L) compared with C. albicans or C. glabrata for CPZ. This drug was more 
active against C. krusei, Cr. neoformans, Rhizopus spp, Mucor spp, A. 
fumigatus, A. niger, S. apiospermun and S. prolificans than against C. 
albicans, C. glabrata, Absidia spp, A. flavus, A. ustus, and A. terreus. (Fig 2 
A). For the all strains tested, TFP was more active than CPZ, with MIC values 
lower than 60 mg/L.  
Table 3 Susceptibility in vitro of Aspergillus spp. to ant ifungal and antipsychotic 
drugs 
 
MIC (mg/L) Strain (no. of 
isolates) and 
drug 
GM MIC50 MIC90 Range 
A. fumigatus  
(20) 
    
Amphotericin B 0.5 0.5 1 0.25-1 
Fluconazole ND ND ND ND 
Itraconazole 2.64 0.5 32 0.5-32 
Chlorpromazine 42.2 32 64 32-64 
Trifluopherazine 34.3 32 32 32-64 
Thio thixene 512 512 512 512 
Chlorprothixene 46.8 64 64 32-64 
Fluphenazine 64 64 64 64 
A. flavus  (10)     
Amphotericin B 2.14 2 4 1-4 
Fluconazole ND ND ND ND 
Itraconazole 0.81 1 2 0.25-2 
Chlorpromazine 64 64 64 32-128 
Trifluopherazine 64 64 64 64 
Thio thixene >512 >512 >512 >512 
Chlorprothixene 64 64 64 64 
Fluphenazine 68.6 64 64 64-128 
A. niger  (10)     
Amphotericin B 1 0.5 4 0.5-4 
Fluconazole ND ND ND ND 
Itraconazole 0.63 0.5 1 0.25-1 
Chlorpromazine 24.2 16 64 16-64 
Trifluopherazine 21.1 16 32 16-32 
Thio thixene 256 256 256 256 
Chlorprothixene 17.1 16 16 16-32 
Fluphenazine 34.3 32 32 32-64 
A. ustus  (10)     
Amphotericin B 1.52 1 2 1-4 
Fluconazole ND ND ND ND 
Itraconazole 2 4 8 0.5-8 
Chlorpromazine 64 64 64 64 
Trifluopherazine 34.3 32 32 32-64 
Thio thixene 256 256 256 256 
Chlorprothixene 32 32 32 32 
Fluphenazine 64 64 64 64 
A. terreus  (10)     
Amphotericin B 2.46 2 4 1-4 
Fluconazole ND ND ND ND 
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Table 4 Susceptibility in vitro of Scedosporium apiospermun and S. prolificans to antifungal and antipsychotic drugs 
 
 
MIC (mg/L) Strain (no. of isolates) 
and drug GM MIC50 MIC90 Range 
S. apiospermum  (10)     
Amphotericin B 1.62 2 4 0.5-8 
Fluconazole ND ND ND ND 
Itraconazole 0.81 1 4 0.12-4 
Chlorpromazine 48.5 64 64 32-64 
Trifluophe razine 39.4 32 64 32-128 
Thiothixene 256 256 256 256 
Chlorprothixene 16 16 32 8-32 
Fluphenazine 59.7 64 64 32-64 
S. prolificans  (30)     
Amphotericin B 22.6 >16 >16 4->16 
Fluconazole ND ND ND ND 
Itraconazole >16 >16 >16 >16 
Chlorpromazine 36.5 32 64 32-64 
Trifluophe razine 34.3 32 32 32-64 
Th iothixene 222.8 256 256 128-256 
Chlorprothixene 16.3 16 32 8-64 
Fluphenazine 62.4 64 64 32-64 
0.00
30.00
60.00
90.00
0.00
30.00
60.00
90.00
0.00
30.00
60.00
90.00
0.00
30.00
60.00
90.00
1   2    3   4    5    6    7    8     9  10  11  12  13  14 1   2    3   4    5    6    7    8     9  10  11  12  13  14
A
C
B
D
Fig 2.  MICs comparation between 4  antipsychotics 
A: Chlorpromazine; B: Trif luopherazine; C: Fluphenazine; D: Chlorprothixene  
1-C. albicans; 2-C. krusei; 3-C. glabrata; 4-C. neoformans; 5- Absidia spp; 6- Rhizopus spp; 7- Mucor spp; 8- A. fumigatus; 
9- A. flavus; 10- A. niger; 11- A. ustus; 12- A. terreus; 13-S. apiospermum; 14- S. prolificans
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The drug was more active against Cr. neoformans and Rhizopus spp 
compared with A. flavus  (Fig 2 B). For FNP low MICs were observed for Cr. 
neoformans, Rhizopus spp, Mucor spp, A. niger, A. terreus, S. apiospermum 
and S. prolificans  (Fig 2 C). 
CPT showed the highest in vitro activity against all fungi tested with the 
exception of C. krusei and A. flavus  (Fig 2 D).  Considering the MIC/MFC 
ratios, fungistatic activity was observed for CPZ, TFP, CPT and FNP (Data 
not shown). 
 
Discussion 
The phenotiazines are a group of potent pharmacological agents with 
neuroleptic, antiemetic, antihistaminic, anticholinergic, and sedative activities 
10. In the present study we investigated the antifungal activity of these 
compounds against a collection of isolates that included strains which are 
difficult to treat, due to reduced susceptibility to azoles including C. albicans, 
C. krusei and C. glabrata,  itraconazole resistant Aspergillus strains, AMB-
resistant A. terreus11,12, S. apiospermun and S. prolificans which are 
considered multiresistant to conventional antifungal drugs 13-15.  
CPZ, TFP, FNP and CPT showed moderate in vitro activity against Candida, 
Aspergillus, zygomycetes and Scedosporium at concentrations below 100 
mg/L. These concentrations are beyond the achievable plasma 
concentrations in humans that vary between 0.5 and 1 mg/L. Although the 
plasma concentration of these drugs is low, they may be concentrated to as 
much as 70 to 100 fold the plasma level in tissues and macrophages 22,23. In 
autopsy studies  concentrations of phenotiazines up to 190 mg/g were found 
in liver 24. The in vitro activity observed in this study is comparable with that 
shown in previous studies for Candida species (10 to 40 mg/L) 25,26 and Cr. 
neoformans (40 mg/L) 27.    
In a murine model of invasive candidosis the survival of infected control mice 
with C. albicans was 14% while of those mice receiving daily injections of 4.2 
mg/kg of body weight of trifluopherazine, 85.7% survived. Similar results were 
obtained in a Cr. neoformans in vivo model in which the survival increased 
from 10% to 70% for mice receiving daily injections of 7 mg/kg of body weight 
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of trifluopherazine 25. This indicates that representatives of this class of drugs 
are active in vivo despite moderate activity in vitro. 
Although the mechanism of action of these drugs against fungi is unknown,  
they induce multiple effects in other eukaryotic cells including modification of 
membranes, alteration of cyclic nucleotid metabolism and action on 
calmodulin25,28,29. Since the presence of calmodulin in Candida was 
described, this could act as target for these drugs in fungi 30. A. nidulans 
contains genes encoding for Ca+2 binding proteins that are essential for 
growth 31. Although no data are available on the presence of calmodulin in 
other Aspergillus species, zygomycetes or Scedosporium, it is possible that 
they also have calmodulin or a calmodulin-like gen, that acts as target. 
Trifluopherazine consistently killed a higher percent of melanized Cr. 
neoformans than nonmelanized Cr. neoformans. Although the mechanism by 
which melanization enhanced the susceptibility of Cr. neoformans to this 
phenotiazine is unknown, several lines of evidence implicate a role for 
melanin (or melanin precursor) in this effect and therefore could be an 
alternative explanation for the antifungal  effects 27,32,33. 
Another possible mechanism of action is the inhibition of MDR (molecular 
drug resistant) efflux pumps. Phenotiazine and thioxanthene could act by 
inhibition of these pumps. This could reverse phenotypic resistance of fungal 
pathogens to azoles when given in combination. Also these drugs are 
dopamine receptor antagonists and calmodulin inhibitors, and have modest 
but broad antimicrobial activities 34-36.  
The thioxanthenes demonstrate geometric stereoisomerism. In the clinical 
setting only the cis  form possesses neuroleptic activity, but both the cis and 
trans forms have roughly equal antimicrobial potency  34,37,38. 
Phenotiazines are not suitable for the treatment of patients with fungal 
infection, given the number of (neuroleptic) side-effects, but the trans-
geometric stereoisomerism without neuroleptic effect is of interest since the 
antifungal activity is enhanced and the pharmacokinetic properties of this 
class of compounds maintained.  
Since phenotiazines reach high concentrations in the brain, lungs, gut and 
liver10 these compounds or derivates could be particulary suitable for 
treatment of fungal meningitis, encephalitis or disseminated infection caused 
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by fungal pathogens. Combinations studies are of interest given the different 
target than the conventional agents. 
In summary, the results of this study demonstrate that antipsychotic drugs are 
active in vitro against a broad range of difficult treat yeasts and molds. Further 
studies in animal models with drugs from this class alone and in combination 
with conventional antifungal agents are necessary to gain more insight in the 
potential role of these drugs. 
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Running heading : antifungal combination in zygomycetes  
 
Abstract 
The in vitro interactions between amphotericin B and either rifampicin, 
flucytosine, or terbinafine and between terbinafine and voriconazole were 
tested against 35 strains of zygomycetes comprising of 15 Rhizopus spp., 10 
Absidia corymbifera, 6 Mucor spp., 3 Rhizomucor spp., and 1 Cunninghamella 
bertholletiae. Drug combinations were tested by the NCCLS M38-P technique 
modified for a broth microdilution checkerboard procedure. The interaction 
between amphotericin B and rifampicin was synergistic (fractional inhibitory 
concentration index of ≤ 0.5) in 69% of cases and additive in 31% of cases. 
Synergy was observed for all A. corymbifera isolates and for 40% of Rhizopus 
spp. isolates. Flucytosine alone was inactive against all the isolates and, upon 
combination with amphotericin B, synergy was not achieved. The combination 
of amphotericin B with terbinafine was synergistic for 20% of strains and, 
there were no differences between genera. The interaction between 
terbinafine and voriconazole was synergistic for 44% of strains with a 
significant difference between genera. Synergy was not observed for A. 
corymbifera but was demonstrated for 60% of the Rhizopus spp. isolates. No 
antagonism was observed with any combination. These in vitro data suggest 
that antifungal combination therapy could be of interest for the management 
of zygomycosis and should be further investigated. 
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Introduction 
Zygomycosis is an aggressive infection occurring mostly in patients with 
diabetic ketoacidosis or neutropenia or in patients receiving corticosteroids 
(36). Within the zygomycetes, members of the genera Rhizopus, Mucor, and 
Absidia are the most commonly isolated microorganisms in patients with 
zygomycosis (36). Despite antifungal therapy, mortality in patients with 
zygomycosis remains very high, particularly in the pulmonary and 
disseminated forms of the disease (21, 26, 44), and clearly new therapeutic 
approaches are needed. Intravenous amphotericin B is the drug of choice for 
treatment of zygomycosis but its use is limited by its narrow therapeutic index 
(14). Combination therapy is one approach to improve activity and/or reduce 
toxicity of antifungal drugs (35). Few studies have been carried out to test 
antifungal combinations against zygomycetes in vitro (5, 43) or in animal 
models of zygomycosis (42).  
Combination of amphotericin B with rifampicin has proven to be synergistic in 
vitro against Saccharomyces cerevisiae (27), Candida spp. (4,8), 
Cryptococcus neoformans (13), dimorphic fungi (25, 37), Aspergillus (19, 24), 
and Rhizopus (5). Nevertheless, in vitro studies are largely dependent on the 
methodology used and this could explain, at least in part, that in animal 
models of fungal infections, results for this combination have been conflicting 
(10, 16). 
Interaction between amphotericin B and 5-fluorocytosine has been shown to 
be additive or synergistic against Candida and Cryptococcus in vitro, and in 
vivo in animal models as well as in patients (35). Although in vitro studies 
have reported indifferent to synergistic and in some instances antagonistic 
interactions in Aspergillus (7, 19) this combination may have a role for the 
management of cerebral aspergillosis in patients (41). 
Terbinafine is a sterol biosynthesis inhibitor (34), primarily used for superficial 
mycoses but its current applications are extending (33). Although the potential 
of this antifungal for zygomycosis is unknown, some zygomycete isolates 
exhibit low MICs for terbinafine (22). It has been shown that combination of 
amphotericin B with terbinafine displayed synergistic interaction in Candida 
albicans (2) and in Aspergillus spp. (39). Moreover, terbinafine in combination 
with amphotericin B has been used successfully in patients for the treatment 
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of aspergillosis (40) and zygomycosis (11, 31). Synergy between terbinafine 
and azoles has also been demonstrated in yeasts (2,3,15) and in filamentous 
fungi (28, 39, 45). Although interaction between terbinafine and itraconazole 
has been documented in several studies the potential of combination of 
terbinafine with voriconazole has rarely been investigated (39, 45). 
The aim of this study was to investigate the in vitro interaction of amphotericin 
B with rifampicin, 5-fluorocytosine, or terbinafine as well as the interaction of 
terbinafine with voriconazole against zygomycete strains belonging to different 
genera. 
  
Materials and methods 
Test isolates. A total of 35 zygomycete isolates (from our private collection), 
mostly of clinical origin, belonging to different genera of the order Mucorales 
were tested. These comprised 15 Rhizopus spp. (8 R. oryzae and 7 R. 
microsporus), 10 Absidia corymbifera, 6 Mucor spp. (3 M. hiemalis, 1 M. 
circinelloides, 1 M. racemosus, and 1 M. rouxii), 3 Rhizomucor spp. (2 R. 
pusillus and 1 M. miehei), and 1 Cunninghamella bertholletiae. All isolates 
were cultured from frozen stock on Sabouraud dextrose agar (supplemented 
with 0.02% chloramphenicol) for 7 days at 30°C to ensure purity and viability. 
Two reference strains, Candida krusei ATCC 6258 and C. parapsilosis ATCC 
22019 were included to ensure quality control. 
Medium. RPMI 1640 medium with L-glutamine but without sodium 
bicarbonate (GIBCO BRL, Life Technologies, Woerden, The Netherlands) 
buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany) was used as test 
medium. 
Inoculum. Isolates were grown on Sabouraud dextrose agar for 7 days at 
30°C and stock spore suspensions were prepared by washing the surface of 
the slants with 2 ml of sterile saline containing 0.05% Tween 80. Spore 
suspensions were counted with a hemacytometer and then diluted into RPMI 
to a concentration of 2x104 spores/ml (two times final concentration). 
Inoculum sizes were checked by quantitative colony counts on Sabouraud 
dextrose agar. 
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Antifungal susceptibility testing. Drug combinations were tested using the 
guidelines of the National Committee for Clinical Laboratory Standards 
(NCCLS) M38P-document (29) modified for a broth microdilution 
checkerboard procedure. 
The drugs that were tested included voriconazole (Pfizer Central Research, 
Sandwich, United Kingdom), terbinafine (Novartis Pharma, Basel, 
Switzerland), 5-fluorocytosine (ICN Pharmaceuticals, Zoetermeer, The 
Netherlands), and amphotericin B (Bristol-Myers Squibb, Woerden, The 
Netherlands), and rifampicin (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). For stock solutions drugs were dissolved in dimethylsulfoxide, 
except for 5-fluorocytosine which was dissolved in water. The drug dilutions 
were prepared as four times the strength of the final concentration by 
following the additive drug dilution NCCLS scheme (29). For the combination 
of terbinafine with either voriconazole or amphotericin B a checkerboard with 
two-fold dilutions of each drug were used. The final concentrations of the 
antifungal agents were 0.03 to 2 µg/ml for amphotericin B, 0.5 to 32 µg/ml for 
voriconazole and either 0.004 to 2 µg/ml or 0.25 to 128 µg/ml for terbinafine 
depending on the susceptibility of the tested isolates. For the combination of 
amphotericin B with either rifampicin or 5-fluorocytosine a limited 
checkerboard with two-fold dilutions of amphotericin B and four-fold dilutions 
of the other drug was used. The final concentrations were 0.008 to 4 µg/ml for 
amphotericin B, 0.25 to 16 µg/ml for rifampicin (i.e. 4 dilutions were tested : 
0.25, 1, 4, and 16 µg/ml), and 8 to 128 µg/ml for 5-fluorocytosine (i.e. 3 
dilutions were tested : 8, 32, and 128 µg/ml). Growth control wells containing 
medium plus 0.5% of the corresponding solvent were included. Microdilution 
trays were kept at -70oC until the day of testing. 
Incubation and MIC determination. On the day of the test, each well of the 
microtiter plates containing 100 µl of the diluted drug concentrations was 
inoculated with 100 µl of  the inoculum suspension. Microtiter plates were 
incubated at 37oC and MICs were determined after 24h of incubation. MIC 
determination was done in duplicate with similar results. 
Microtiter plates were read visually with the aid of a concave mirror, and the 
growth in each well was compared with that of the growth control. Each well 
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was then given a numerical score according to the NCCLS guidelines : 4, no 
reduction in growth; 3, growth reduction of 25%; 2, growth reduction of 50%; 
1, growth reduction of 75% or more; and 0, absence of growth (optically 
clear). For the combination of amphotericin B with rifampicin or 5-
fluorocytosine MIC endpoints were defined as the lowest drug concentration 
(tested alone or in combination) which had a score of 0 (MIC-0). For the 
combination of terbinafine with voriconazole MIC-2 was used as endpoint for 
both drugs, alone or in combination. For the combination of terbinafine with 
amphotericin B, MIC-0 was used for amphotericin B alone and MIC-2 was 
used for terbinafine alone and for both drugs in combination. The fractional 
inhibitory concentrations (FIC) of both drugs used in combination were 
calculated and added to obtain the FIC indexes (9), as follow : FIC index = 
(MICA in combination / MICA alone) + (MICB in combination / MICB alone). 
Drug interactions were defined as synergy if the FIC index was ≤ 0.5, 
additivity if the FIC index was > 0.5 and ≤ 1, indifference if the FIC index was 
> 1 and ≤ 4, and antagonism the FIC index was > 4. For calculation, the high 
off-scale MICs were converted to the next highest concentration and the low 
off-scale MICs were left unchanged.  
 
 
Statistical analysis : the number of strains showing synergy within the 
different genera were compared by the Fischer's exact test. Statistical 
significance was defined as P ≤ 0.05. 
 
 
Results 
Combination of amphotericin B with rifampicin or 5-fluorocytosine. The 
MICs of the drugs alone, the lowest FIC indices and the corresponding MICs 
of the drugs in combination for the 35 isolates are summarized in Table 1. The 
geometric mean MIC and the MIC90 of amphotericin B were 0.24 and 1 µg/ml, 
respectively. Only one strain (C. bertholletiae) showed a high amphotericin B 
MIC of 2 µg/ml. Growth of all isolates was not inhibited by rifampicin (MIC > 
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16 µg/ml) with the exception of two Rhizomucor spp. isolates that exhibited an 
MIC of 16 µg/ml. 
The interaction between amphotericin B and rifampicin was synergistic in 69% 
of the cases and additive in 31% of the cases. Indifference and antagonism 
were not observed (highest FIC indices ranged from 0.5 to 2.02). For the 
synergistic interactions the median concentration of amphotericin B in 
combination was 0.03 µg/ml  (range : 0.008 to 0.25 µg/ml) and the median 
concentration of rifampicin in combination was 4 µg/ml (range : 1 to 16 µg/ml). 
Synergism was observed for all the A. corymbifera isolates (P < 0.0028 
compared with Rhizopus spp.), for 40% of the Rhizopus spp. isolates and for 
most of the other species (Table 4). 
5-fluorocytosine alone was inactive against all the isolates (MIC > 128 µg/ml). 
Upon combination, synergy was not achieved. Additivity or indifference was 
observed for all the strains. Antagonism was not observed (highest FIC 
indices ranged from 0.75 to 2.25. 
Combination of terbinafine with amphotericin B. The results of the 
checkerboard studies of the combination between terbinafine and 
amphotericin B are presented in Table 2. Terbinafine MICs ranged from 0.015 
to > 128 µg/ml. R. oryzae and Mucor spp. were the species that exhibited the 
highest MICs of terbinafine. Synergistic interactions were observed for 20% of 
the strains and additive or indifferent interactions were noted for 80% of the 
strains. There were no antagonistic interactions (highest FIC indices ranged 
from 0.62 to 2.12 [Figure 1]). For the synergistic interactions the median 
concentration of amphotericin B in combination was 0.125 µg/ml  (range : 0.03 
to 0.5 µg/ml) and the median concentration of terbinafine in combination was 
0.25 µg/ml (range : 0.015 to 8 µg/ml). The percentage of isolates showing 
synergism was not significantly different between species (Table 4). 
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Combination of terbinafine with voriconazole. The mode of interaction 
between terbinafine and voriconazole is summarized in Table 3. The 
geometric mean MIC and the MIC90 of voriconazole were 7.8 and 32 µg/ml, 
respectively.  
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The interaction between terbinafine and voriconazole was synergistic for 44%  
of the strains and additive or indifferent for 56% of the strains. Antagonism 
was not observed (highest FIC indices ranged from 0.27 to 2.5. 
 
 
 
 
 
Table 2 : Drug interaction of terbinafine in combination with amphotericin B against 35 isolates of zygomycetes 
Isolate MIC (µg/ml) of the drugs 
alonea 
MIC (µg/ml) of the drugs in 
the combination TER / AMBb 
Lowest FIC index 
for the combination 
TER / AMB 
 TER AMB    
Rhizopus oryzae 593 > 128 1 0.25 / 0.5 0.51 
Rhizopus oryzae 1523 > 128 2 0.25 / 0.5 0.25 
Rhizopus oryzae 3440 > 128 1 0.25 / 0.5 0.51 
Rhizopus oryzae 5618 > 128 0.5 0.25 / 0.5 1 
Rhizopus oryzae 6142 > 128 1 8 / 0.125 0.16 
Rhizopus oryzae 6373 > 128 0.5 0.25 / 0.25 0.51 
Rhizopus oryzae 9285 > 128 0.5 0.25 / 0.5 1 
Rhizopus oryzae A1925 > 128 1 0.25 / 0.5 0.51 
Rhizopus microsporus 23 0.125 0.5 0.03 / 0.125 0.5 
Rhizopus microsporus 190 0.25 0.5 0.004 / 0.25 0.52 
Rhizopus microsporus  410 0.06 0.5 0.004 / 0.25 0.56 
Rhizopus microsporus 1185 0.125 0.25 0.004 / 0.25 1.03 
Rhizopus microsporus 5005 0.125 0.5 0.03 / 0.125 0.5 
Rhizopus microsporus 5816 0.06 0.25 0.004 / 0.25 1.06 
Rhizopus microsporus A551 0.06 0.25 0.004 / 0.125 0.56 
Absidia corymbifera 24 0.03 0.25 0.03 / 0.03; 0.004 / 0.25 1.12 
Absidia corymbifera 319 0.03 0.25 0.03 / 0.03; 0.004 / 0.25 1.12 
Absidia corymbifera 911 0.125 0.25 0.06 / 0.03 0.62 
Absidia corymbifera 1184 0.03 0.25 0.004 / 0.125 0.62 
Absidia corymbifera 2134 0.06 0.125 0.03 / 0.03 0.75 
Absidia corymbifera 2543 0.06 0.25 0.004 / 0.25 1.06 
Absidia corymbifera 3113 0.06 0.25 0.004 / 0.25 1.06 
Absidia corymbifera 3114 0.06 0.25 0.015 / 0.03 0.37 
Absidia corymbifera 4095 0.06 0.125 0.03 / 0.03 0.75 
Absidia corymbifera 6429 0.06 0.25 0.004 / 0.25 1.06 
Mucor circinelloides 5141 2 0.5 0.25 / 0.25 0.62 
Mucor hiemalis 21 4 0.25 2 / 0.125 1 
Mucor hiemalis 175 > 128 0.5 8 / 0.125 0.28 
Mucor hiemalis 1379 > 128 0.25 0.5 / 0.125 0.51 
Mucor racemosus 8166 0.015 0.25 0.004 / 0.125 0.75 
Mucor rouxii 1183 1 0.25 0.25 / 0.06 0.5 
Rhizomucor miehei 4839 0.06 0.125 0.004 / 0.125 1.06 
Rhizomucor pusillus 22 0.06 0.125 0.004 / 0.125 1.06 
Rhizomucor pusillus 9149 0.06 0.25 0.004 / 0.125 0.56 
Cunninghamella bertholletiae 569 0.06 2 0.015 / 1 0.75 
a TER, terbinafine; AMB, amphotericin B. b Combination corresponding to the lowest FIC index. When the lowest FIC index was f
ound for two different combinations, MIC of the drugs for both combinations are reported. 
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For the synergistic  interactions the median concentration of terbinafine in 
combination was 0.5 µg/ml  (range : 0.015 to 16 µg/ml) and the median 
concentration of voriconazole in combination was 1 µg/ml (range : 0.5 to 8 
µg/ml). Synergism was detected for 60% of the Rhizopus spp. isolates (Table 
4). In contrast, no synergistic interaction was observed for A. corymbifera (P < 
0.0028 compared with Rhizopus spp., P < 0.0031 compared with other 
species). 
 
 
 
 
 
 
 
 
 
Table 3 : Drug interaction of terbinafine in combination with voriconazole against 35 isolates of zygomycetes 
Isolate MIC (µg/ml) of the drugs alonea MIC (µg/ml) of the drugs 
in the combination TER 
/ VRZb  
Lowest FIC index for 
the combination TER 
/ VRZ  
 TER VRZ   
Rhizopus oryzae 593 > 128 16 0.25 / 16 1 
Rhizopus oryzae 1523 > 128 8 8 / 1 0.16 
Rhizopus oryzae 3440 > 128 8 4 / 1 0.14 
Rhizopus oryzae 5618 > 128 16 0.25 / 16 1 
Rhizopus oryzae 6142 > 128 16 8 / 4 0.28 
Rhizopus oryzae 6373 > 128 4 4 / 0.5 0.14 
Rhizopus oryzae 9285 > 128 8 16 / 0.5 0.12 
Rhizopus oryzae A1925 > 128 8 16 / 0.5 0.12 
Rhizopus microsporus 23 0.06 4 0.03 / 0.5 0.62 
Rhizopus microsporus 190 0.125 4 0.06 / 0.5 0.62 
Rhizopus microsporus  410 0.06 2 0.015 / 1 0.75 
Rhizopus microsporus 1185 0.125 8 0.03 / 0.5 0.31 
Rhizopus microsporus 5005 0.125 8 0.03 / 1 0.37 
Rhizopus microsporus 5816 0.06 4 0.015 / 0.5 0.37 
Rhizopus microsporus A551 0.06 4 0.03 / 0.5 0.62 
Absidia corymbifera 24 0.06 4 0.03 / 0.5 0.62 
Absidia corymbifera 319 0.03 2 0.015 / 0.5 0.75 
Absidia corymbifera 911 0.06 4 0.03 / 0.5 0.62 
Absidia corymbifera 1184 0.03 2 0.015 / 0.5 0.75 
Absidia corymbifera 2134 0.06 8 0.03 / 0.5 0.56 
Absidia corymbifera 2543 0.06 8 0.03 / 4 1 
Absidia corymbifera 3113 0.06 8 0.03 / 4 1 
Absidia corymbifera 3114 0.06 4 0.03 / 0.5 0.62 
Absidia corymbifera 4095 0.06 8 0.03 / 2 0.75 
Absidia corymbifera 6429 0.06 8 0.06 / 0.5; 0.004 / 8 1.06 
Mucor circinelloides 5141 4 32 0.5 / 1 0.16 
Mucor hiemalis 21 2 > 32 0.5 / 4 0.31 
Mucor hiemalis 175 4 > 32 0.5 / 8 0.25 
Mucor hiemalis 1379 > 128 16 1 / 4 0.25 
Mucor racemosus 8166 NDc ND ND / ND ND 
Mucor rouxii 1183 0.5 > 32 0.25 / 16 0.75 
Rhizomucor miehei 4839 0.125 2 0.03 / 0.5 0.5 
Rhizomucor pusillus 22 0.06 4 0.03 / 0.5 0.62 
Rhizomucor pusillus 9149 0.06 4 0.03 / 0.5 0.62 
Cunninghamella bertholletiae 569 0.06 16 0.015 / 0.5 0.28 
a TER, terbinafine; VRZ, voriconazole. b Combination corresponding to the lowest FIC index. When the lowest 
 FIC index was found for two different combinations, MIC of the drugs for both combinations are reported. 
 c ND, not determined. 
Table 4 : Summary of drug interaction for the four combinations tested 
 
Genera (no. of strains) % of isolates showing synergism for the following 
combinationa 
 AMB / RIF AMB / 5FC TER / AMB TER / VRZ 
Rhizopus spp. (15) 40 0 27 60 
Absidia spp. (10) 100 0 10 0 
Other (10) 80 0 20 67 
All isolates (35) 69 0 20 44 
a AMB, amphotericin B; RIF, rifampicin; 5FC, 5-fluorocytosine; TER, terbinafine; VRZ, 
voriconazole. 
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Discussion 
Zygomycosis remains a very severe infection. The overall mortality of 
localized pulmonary zygomycosis is 65% (44) and > 95% in disseminated 
forms of the disease (21, 44). This poor outcome could be related in part to 
the fact that the diagnosis is difficult and therapy then often delayed. Even in 
the case of high-dose AMB treatment associated with aggressive surgery 
mortality remains high. Combination therapy is commonly used for difficult-to-
treat bacterial and some fungal infections and could be a useful strategy in 
zygomycosis. In patients with zygomycosis, combination therapy with 
amphotericin B and rifampicin (5, 6, 30) or amphotericin B and terbinafine (11, 
31) have been reported. Nevertheless, it is not possible to draw conclusions 
from these anedoctal case reports. Few studies have been done to evaluate 
the potential of drug combinations against zygomycetes (5, 42, 43). In vitro 
data are limited to a study showing synergism between amphotericin B and 
rifampicin in Rhizopus spp. (5). In a murine model of pulmonary 
mucormycosis due to Rhizopus oryzae it has been shown that combination of 
fluconazole with quinolones was effective although each of the drugs were 
inactive when used alone (42). It has to be pointed out that positive interaction 
between these drugs was not demonstrated in vitro (43). 
In the present study we have tested, by using an NCCLS-based technique, 
four combinations against a large panel of zygomycetes strains belonging to 
different genera. 
We found synergistic interactions between amphotericin B and rifampicin at 
clinically relevant concentrations of rifampicin (the median concentration of 
rifampicin in combination was 4 µg/ml). The Cmax of rifampicin following 
administration of a 600 mg dose ranges from 9.6 to 25 µg/ml (32). 
Interestingly, there was a clear difference between different genera, a 
synergistic interaction was obtained for all the A. corymbifera strains 
compared to 40% among the Rhizopus spp. strains. In several studies the in 
vitro interaction between amphotericin B and rifampicin has been tested 
against medically important fungi. Although different susceptibility testing 
methods and different definitions of synergism have been used, synergistic 
interaction has been usually documented for yeasts (4, 8, 13, 27, 38). For 
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hyphomycetes, synergistic interactions were found in Aspergillus spp. (7, 19, 
24) but not in Fusarium spp. (17). It has also been shown that rifampicin acted 
synergistically with amphotericin B against dimorphic fungi in vitro (20, 25, 
37). Nevertheless, in animal models, results have been conflicting. Although 
potentiation of amphotericin B by rifampicin has been demonstrated for the 
treatment of murine aspergillosis (1) or histoplasmosis and blastomycosis 
(23), the combination was not beneficial in the treatment of disseminated 
candidiasis in mice (10, 16). The usefulness of this combination in 
zygomycosis remains a open question and is supported only by in vitro results 
and few case reports from which it is not possible to draw clear conclusions. 
Nevertheless, as zygomycosis remains a very difficult-to-treat infection and 
because clinical trials for rare infections are difficult to conduct, it is probably 
of interest to test this combination in animal models, particularly for Absidia 
infections. 
In the present study the combination of amphotericin B with 5-fluorocytosine 
was not synergistic. This combination is beneficial for the treatment of 
cryptococcal meningitis and selected Candida infections (35) and possibly for 
Aspergillus infections of the central nervous system (41). 
 We found synergistic interactions between amphotericin B and terbinafine for 
20% of the strains with a median concentration of terbinafine in combination 
of 0.25 µg/ml, which is within the range achievable in serum (12). It has to be 
noticed that the concentration of terbinafine in the lung is two to seven times 
higher than the concentration in plasma (40). In vitro studies have shown 
synergistic interactions between amphotericin B and terbinafine against 
Candida albicans (2) and Aspergillus spp. (39). Moreover, this combination 
has been used in patients with zygomycosis (11, 31) and aspergillosis (40). 
The good safety profile of terbinafine and the possibility to use high dosage up 
to 2000 mg/day (Vazquez, J. A., A. Lamarca, R. Schwartz, R. Ramirez, L. 
Smith, R. Pollard, J. Gill, A. Fothergill, L. Ince, J. Wirzman, J. Perez, and J. 
Felser, Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 
1418, 2000) warrants further evaluation of the combination of terbinafine with 
polyenes against zygomyctes and other filamentous fungi. 
Although the first-line therapy for zygomycosis remains parenteral 
amphotericin B, we have tested the combination of voriconazole with 
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terbinafine and found synergistic interaction between these two drugs in 44% 
of isolates. There was a significant difference between genera; synergism was 
not observed for A. corymbifera but was demonstrated for 60% of the 
Rhizopus strains. Moreover, the median concentrations of terbinafine and 
voriconazole in combination were 0.5 and 1 µg/ml, respectively. The Cmax of 
voriconazole at steady-state is 2.7 to 6 µg/ml (18). Terbinafine and azoles 
inhibit different steps of the ergosterol biosynthesis pathway and this could be 
the mechanistic explanation of the observed synergism when the two drugs 
are combined. In vitro synergism has been demonstrated for the combination 
of terbinafine with either fluconazole or itraconazole against C. albicans (2, 3), 
S. prolificans (28) and Aspergillus spp. (39) and these combinations have also 
been used in humans. Few studies have tested the interaction of terbinafine 
with voriconazole. In two recent studies it has been shown that terbinafine in 
combination with voriconazole displayed potent synergy against C. albicans 
(45) and Aspergillus spp. (39). 
In summary, the results of this study demonstrated that some antifungal 
combinations are synergistic in vitro against zygomycetes, with different 
results for Rhizopus spp. and A. corymbifera. Further studies in animal 
models of zygomycosis are necessary to confirm the clinical potential of these 
combinations. 
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ABSTRACT 
 
To develop new approaches for the treatment of invasive infections caused by 
Scedosporium prolificans, the in vitro interaction between amphotericin B and 
pentamidine against 30 clinical isolates was evaluated using a checkerboard 
microdilution method based on the National Committee for Clinical Laboratory 
Standards M38-P guidelines. The interaction between the drugs was analyzed 
using fractional inhibitory concentration index (FICI) analysis and response 
surface modeling. Amphotericin B alone was inactive against all the isolates. 
The geometric mean MIC for pentamidine was 57 µg/ml (range, 8 to 256 
µg/ml; MIC at which 50% of the isolates tested were inhibited [MIC50], 64 
µg/ml; MIC90, 128 µg/ml). The combination was synergistic against 28 of 30 
isolates (93.3%) by FICI analysis and 30 of 30 (100%) by response surface 
modeling analysis. Antagonism was not observed.  
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The in vitro susceptibility of Scedosporium prolificans to antifungal agents has 
been tested in several studies (5,7,22), and although the methodological 
conditions differed in the various studies, in general, their results correlated 
with the observed poor clinical outcomes. The new azoles, such as 
ravuconazole, voriconazole, and posaconazole, showed poor in vitro activity 
(5,7), with the exception of the experimental azole UR-9825, which showed 
some activity against S. prolificans (5). Pentamidine (PN) displayed good in 
vitro and in vivo activity against Pneumocystis carinii, a microorganism that 
now is believed to belong to the fungal kingdom (12,24,28). Also, in 
combination with amphotericin B (AMB), the drug displayed in vivo and in vitro 
synergistic activity against other eukaryotic microorganisms such as 
Leishmania donovani (21,28). To develop new therapeutic strategies to treat 
invasive scedosporiosis, we investigated the in vitro activity of AMB and PN, 
alone or in combination, using two different criteria, the fractional inhibitory 
concentration index (FICI) (10) and response surface modeling (13).  
Thirty clinical isolates (3) of S. prolificans were tested. The isolates were 
subcultured on potato dextrose agar (PDA) for 5 to 7 days at 30°C. Candida 
parapsilosis (ATCC 22019) and Candida krusei (ATCC 6258) were used as 
quality control strains. All isolates were tested in duplicate on two different 
days. Conidia were obtained from fresh cultures each time. All solutions were 
prepared ex novo with powders from the same lot.  
MICs were determined by a broth microdilution method according to the 
National Committee for Clinical Laboratory Standards guidelines (M38-P) 
(25).  
Conidia were collected with a cotton stick and suspended in sterile water. 
After the heavy particles were allowed to settle, the turbidity of the 
supernatants was measured spectrophotometrically (Spectronic 20D; Milton 
Roy, Rochester, N.Y.) at 530 nm and the transmission was adjusted to 68 to 
70% and diluted 1:50 in RPMI medium to obtain two times the desired 
inoculum concentration. The inoculum size was verified by determination of 
the number of viable CFU after plating serial dilutions of the inoculum onto 
Sabouraud dextrose agar. These cultures showed that the final inoculum 
concentrations ranged between 1.5 x 104 and 5 x 104 CFU/ml, which is within 
the recommended upper and lower limits. The drugs used in this study were 
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AMB (Bristol-Myers Squibb, Woerden, The Netherlands) and PN (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany). The final concentrations of the 
drugs ranged from 0.03 to 16 µg/ml for AMB and from 1 to 128 µg/ml for PN. 
AMB was dissolved in dimethyl sulfoxide (Merck, Darmstadt, Germany), and 
PN was dissolved in water.  
Drug dilutions were made in RPMI 1640 medium (with L-glutamine and 
without bicarbonate) (GIBCO BRL, Life Technologies, Woerden, The 
Netherlands) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid 
(MOPS) (Sigma-Aldrich Chemie). Susceptibility testing was performed in 96-
well flat-bottom microtitration plates, which were kept at -70°C until the day of 
testing. After inoculation and agitation, the plates were incubated at 35°C for 
72 h and the MICs were read visually and spectrophotometrically. Growth was 
graded on a scale of 0 to 4 as follows: 4 indicated no reduction in growth, 3 
indicated a 25% reduction of growth, 2 indicated a 50% reduction of growth, 1 
indicated a 75% reduction of growth, and 0 indicated an optically clear well. 
The MIC endpoint was defined as the lowest concentration showing an 
optically clear well or absence of growth (MIC 0, 95% inhibition) for the drugs 
alone as well as for the combination. The optical density (OD) was measured 
with a spectrophotometer (MS2 reader, Titertek-plus; ICN Biomedical Ltd., 
Basingstoke, United Kingdom) at 405 nm. The OD of the blank, to which a 
conidium-free inoculum had been added, was subtracted from the OD values. 
The percentage of growth for each well was calculated by comparing the OD 
of the well with that of the drug-free control.  
The in vitro fungicidal activity (minimal fungicidal concentration [MFC]) of each 
agent was determined by streaking 100 µl from each well that showed 
complete inhibition (95% inhibition or an optically clear well) onto Sabouraud 
dextrose agar plates. The plates were incubated at 35°C for 72 h, the MFC 
was the lowest drug concentration at which there was either no growth or only 
a single colony, which corresponds with 99.9% killing. The drug was 
considered fungicidal if the ratio of MFC to MIC did not exceed a value of 4. If 
the ratio was greater than 4, the activity was considered to be fungistatic (15).  
A two-dimensional, two-agent broth microdilution checkerboard technique was 
used to study the interaction between both drugs. Drug interaction was 
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analyzed by two different methods, the FICI and the response surface model 
of Greco et al. (13, 14).  
FICI values were calculated as follows: MIC of AMB-PN/MIC of AMB + MIC of 
AMB-PN/MIC of PN. The interpretation of the FICI was determined as follows: 
≤0.5, synergistic effect; >0.5 but 1, additive effect; >1 but ≤4, indifferent effect; 
and >4, antagonistic effect (10). In practice, synergism or antagonism 
calculated in this way is equivalent to a reduction or increase of at least two 
dilution steps in the MICs of both drugs when they are combined compared to 
the MICs for the drugs alone.  
Because there is no definition of PN MIC endpoint for fungi, alone or in 
combination with AMB, we used the response surface modeling described by 
Greco et al. (13, 14). The model is described by the formula below and was 
used previously to characterize the interaction of antiviral, antifungal, and 
antineoplastic agents (11,14,20,28a):  
 
where D1 and D2 are the concentrations of drug 1 and drug 2 (AMB and PN), 
IC50,1 and IC50,2 are the concentrations of drug 1 and drug 2 resulting in 50% 
inhibition, E is the measured response, Econ is the control response, m1 and 
m2 are the slope parameters for drugs 1 and 2 in constant ratios, and α is the 
synergism-antagonism interaction parameter (ICα). If α is zero, the 
combination is additive; if α is positive, the interaction is synergistic. A 
negative  value indicates antagonism. The estimate of α has an associated 
95% confidence interval; if the confidence interval does not overlap zero, this 
provides the statistical significance for the estimate of interaction. A computer 
program (ModLab; Medimatics, Maastricht, The Netherlands) was used to fit 
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the data to this model (28a). The program also determined the 95% 
confidence interval for each parameter.  
The MICs of AMB and PN, based on 95% reduction of growth for C. krusei 
(ATCC 6258), were 0.5 and 16 µg/ml, respectively, and for C. parapsilosis 
(ATCC 22019) were 0.25 and 4 µg/ml, respectively. The MICs for the quality 
control strains were within the reference ranges for AMB, but there is no 
reference MIC described for PN.  
AMB was inactive in vitro against most isolates: MIC at which 50% of the 
isolates were inhibited (MIC50) and MIC90 were 32 µg/ml, and the geometric 
mean MIC was 22.62 µg/ml (range, 4 to 32 µg/ml). The geometric mean MIC 
for PN was 57 µg/ml (range, 8 to 256 µg/ml; MIC50, 64 µg/ml; MIC90, 128 
µg/ml). The geometric means of the MFCs of AMB and PN were 30.55 µg/ml 
(range, 16 to 32 µg/ml) and 165 µg/ml (range, 16 to 256 µg/ml), respectively. 
The MFC/MIC ratios were more than 4 for all the strains, indicating fungistatic 
activity.  
Synergism was found for 28 of 30 isolates (93.3%), according to the FICI. The 
remaining two isolates showed an additive effect (Table 1). According to the 
Greco model, AMB and PN showed synergistic interaction against all S. 
prolificans isolates. The 95% confidence interval of the α values did not 
overlap zero, indicating significant synergism (Table 1).  
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Disseminated infection by S. prolificans most commonly occurs in neutropenic 
patients with hematologic malignancies. It is a rapidly fatal infection 
characterized by fever and multiorgan failure. Many patients have been 
treated with AMB and occasionally with other antifungals but commonly with 
unsuccessful outcomes (3, 5, 18).  
PN is an aromatic diamidine that displays multiple effects and is active in vitro 
against a number of different bacteria, protozoa, and fungi, such as 
Blastomyces dermatitidis, Saccharomyces cerevisiae, Candida species, and 
Cryptococcus neoformans (2, 8, 19, 23, 27, 29). Patients who receive 4 mg/kg 
of body weight daily by slow intravenous infusion can achieve a blood 
concentration of 0.5 to 3.2 µg/ml. However, much higher levels are found in 
tissue, with concentrations of up to 56 µg/g in lung, 35 to 300 µg/g in liver, 40 
to 368 µg/g in spleen, and 8.5 to 123 µg/g in kidney tissue (4, 9). When drug 
levels were related to MICs, 20 of 30 of the S. prolificans isolates were 
considered susceptible to this drug in vitro. Considering the MIC/MFC ratios, 
fungistatic activity was observed for PN.  
A promising approach to treatment of invasive scedosporiosis might be that of 
combining antifungal drugs with different mechanisms of action. PN in 
combination with AMB showed synergistic interaction in most of the strains, 
using either the FICI or the Greco model. Several different mechanisms of 
antimicrobial activity have been proposed for PN, such as inhibition of DNA, 
RNA, phospholipid, and protein synthesis (8, 28). However, because the 
mechanism of action is not fully understood, it is difficult to characterize the 
synergistic interaction with AMB.  
AMB in combination with tetracyclines, azithromycin, or rifampin was 
synergistic in vitro against Aspergillus spp. (6, 16, 17, 26). As with PN, the 
above-mentioned antibacterial drugs inhibit the protein synthesis, and this 
could be an explanation of their positive interaction. A disadvantage of the 
combination of AMB and PN was that it caused acute reversible renal failure 
in vivo, and therefore, caution should be used when these agents are given 
concomitantly (1). However, since the most frequent portal of entry of the 
fungus appears to be the respiratory tract, administration of aerosolized PN, 
combined with systemic administration of AMB, could reduce toxicity.  
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In conclusion, this is the first description of activity of PN alone or in 
combination with AMB against S. prolificans in vitro.  
Further studies with this and other combinations in appropriate animal models 
are required to develop therapeutic strategies for treatment of invasive 
scedosporiosis.  
(This work was presented in part at the 41st Interscience Conference on 
Antimicrobial Agents and Chemotherapy, Chicago, Ill., 16 to 19 December 
2001.)  
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Abstract 
The combined effects of antifungal and antibiotic drugs against Exophiala 
spinifera were evaluated in vitro by the chequerboard method, calculated as a 
fractional inhibitory concentration (FIC) index. Amphotericin B was combined 
with flucytosine and ciprofloxacin, whereas itraconazole was combined with 
ciprofloxacin, levofloxacin, lomefloxacin and sulfadiazine. Synergic effects 
were observed for the combinations of itraconazole with ciprofloxacin and 
levofloxacin, and amphotericin B with ciprofloxacin and flucytosine. No 
antagonism was observed for any combination tested.  
 
Keywords: Exophiala, black yeasts, quinolones, drug combinations 
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Black yeast-like fungi are increasingly being recognized as potential human 
pathogens. Clinical pictures include either subcutaneous or systemic 
mycetoma, chromoblastomycosis and phaeohyphomycosis.1 
As model species we selected Exophiala spinifera. Although this is a very rare 
agent of disease in humans, it is one of the most aggressive species of black 
yeast, potentially causing disseminated infections with fatal outcome in 
children and adolescents. In adults, in contrast, infections are mostly localized 
or subcutaneous lesions.2 
The optimal therapy for black yeast infections is controversial. Surgical 
excision, antifungal drug monotherapy or drug combinations have been used, 
but prolonged treatment is needed because relapses often occur. 
Consequently, new approaches to treatment are overdue. 
Quinolones are potent inhibitors of DNA gyrase and are extensively used in 
clinical practice for bacterial infections.3 
Sulphonamides act as competitive antagonists of p-aminobenzoic acid 
(PABA), which is an integral component of the structure of folic acid. 
Decreased folic acid synthesis results 
n a decrease in nucleotides with subsequent growth inhibition.4  Both types of 
drug have favourable pharmacokinetic profiles in cerebrospinal fluid and 
bone.4 
In one report, a nodule on a finger was treated with surgical excision and 
three antifungals, but after a month another lesion appeared in the left arm 
with no healing of the finger lesion. In this case, treatment with co-trimoxazole 
was initiated on diagnosis of a Nocardia superinfection, and after 11 days 
both lesions had improved. This suggests that sulphonamides might be 
effective in treating this infection.5 
Quinolones have a broad spectrum of activity as inhibitors of DNA gyrase, 
type 2 topoisomerase, which is present in prokaryotes and eukaryotes. The 
presence of high levels of topoisomerases I and II has been reported in 
pathogenic fungi.6 Although they are inapplicable as sole antifungal agents, 
quinolones augment the activity of amphotericin B and azoles.7,8 For example, 
in a murine model study of candidiasis, similar survival rates were 
demonstrated in mice treated with fluconazole alone 80 mg/kg/day and in 
those treated with fluconazole (40 mg/kg/day) and ciprofloxacin.8 
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The aim of the present study was to investigate the in vitro activity of 
quinolones and sulfadiazine, either alone or in combination with amphotericin 
B or itraconazole, as well as the combination of amphotericin B and 
flucytosine against E. spinifera strains. 
Thus, for this study eight clinical and two environmental well-documented 
isolates of E. spinifera were used (Table 1). 
 
 
Drugs tested were amphotericin B (Bristol-Myers Squibb, Woerden, The 
Netherlands), itraconazole (Janssen-Cilag, Beerse, Belgium), flucytosine (ICN 
Pharma BV, Zoetermeer, The Netherlands), ciprofloxacin (Bayer AG, 
Leverkusen, Germany), lomefloxacin (Searle Nederland, Maarssen, The 
Netherlands), levofloxacin (Hoechst Pharma, Amsterdam, The Netherlands) 
and sulfadiazine (Sigma-Aldrich Chemie GmbH, Steinheim, Germany). All 
drugs were dissolved in dimethylsulphoxide (DMSO), with the exception of 
flucytosine and ciprofloxacin, which were dissolved in water. 
Two-fold serial dilutions of the drugs were made in RPMI-1640 medium 
(Gibco BRL, Woerden, The Netherlands) to obtain final concentrations that 
ranged from: 0.015 to 8 mg/L for amphotericin B; 0.02 to 1 mg/L for 
itraconazole; 0.25 to 128 mg/L for flucytosine; 0.125 to 8 mg/L for 
ciprofloxacin; 0.09 to 6 mg/L for lomefloxacin; 0.15 to 10 mg/L for levofloxacin; 
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and 2.5 to 160 mg/L for sulfadiazine. RPMI-1640 medium (with L-glutamine, 
without bicarbonate) was buffered to pH 7.0 with 0.165 M MOPS (Sigma-
Aldrich, Steinheim, Germany). 
Tests were performed in 96-well flat-bottom microtitration plates (Corning, 
Ames, MA, USA), which were kept at –70°C until the day of testing. The MIC 
of each drug alone was tested by a broth microdilution method, according to 
NCCLS guidelines (M38-P)9 that provide for testing of polyenes, flucytosine 
and azole antifungal agents against filamentous fungi. 
Conidial suspensions were diluted in RPMI-1640 to obtain twice the desired 
inoculum concentration. A drug-free well containing 0.01% DMSO in the 
medium served as the growth control for the drugs dissolved in this solvent. 
Plates were incubated at 35°C for 72 h. The MICs were determined by 
spectrophotometry. The relative optical densities (ODs) for each well based 
on measurements at 405 nm were calculated (as a percentage) based on the 
following equation: [(OD of drug-containing well – background OD)/(OD of 
drug-free well – background OD)] × 100%. The MIC of each drug alone was 
defined as the lowest concentration of the drug that showed at least 95% 
reduction of growth compared with that of the growth control (MIC-0) for 
amphotericin B, quinolones and sulfadiazine, and for flucytosine and 
itraconazole as the lowest concentration of the drug that showed 50% 
reduction of growth compared with that of the growth control (MIC-2). 
A two-dimensional, two-agent broth microdilution chequerboard method was 
used to study the interaction between the drugs. For all the combinations 
tested, MIC endpoints 
considered were MIC-0 when amphotericin B was combined and MIC-2 when 
itraconazole was combined with the corresponding drug. The FICs of both 
drugs used in combination were calculated and added to obtain the FIC 
indices. The FIC index was calculated as follows: (MIC of drug A + drug 
B/MIC of drug A) + (MIC of drug A + drug B/MIC of drug B). 
Drug interactions were defined as synergic if the FIC index was ≤0.5, 
antagonistic if the FIC index was >4 and noninteractive between 0.5 and 4. 
The MIC of amphotericin B ranged from 0.25 to 2 mg/L; that of itraconazole 
from 0.031 to 0.125 mg/L; that of flucytosine from 2 to 32 mg/L. For 
sulfadiazine and quinolones no 
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activity was found with the drug alone (Table 1). Amphotericin B combined 
with flucytosine showed a synergic effect for five strains and no interaction for 
four. For amphotericin B plus ciprofloxacin, a synergic effect was observed 
against five strains and no interaction for two (Table 2). 
Itraconazole combined with levofloxacin, lomefloxacin and ciprofloxacin 
showed synergic activity against seven, four and six strains, respectively. No 
interaction when combined with itraconazole was observed with six strains for 
lomefloxacin, four strains for ciprofloxacin and three strains for levofloxacin. 
When itraconazole was combined with sulfadiazine, synergic activity was 
observed against five strains and no interaction against three strains (Table 
2). No antagonistic effect was observed in any combination. 
 
Only very few in vitro and animal studies have been carried out with this group 
of fungi. One study, on a central nervous system phaeohyphomycosis in mice 
infected with three different genera of black fungi. Ochroconis constricta 
showed good correlation in vitro–in vivo with amphotericin B, although high 
doses of amphotericin B were needed. For Cladophialophora bantiana, 
flucytosine was the most effective, but no single drug achieved full recovery. 
This drug was also the most effective against Exophiala dermatitidis.11 
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Quinolones and sulfadiazine were selected for this study because of their 
favourable distribution in the body and their ability to enhance antifungal 
activity when used in combination. 
Flucytosine was selected as a classic drug that possesses activity against 
black fungi. Our study indicates that for some isolates, quinolones augmented 
the activity either of itraconazole or amphotericin B when combined, since 
synergic effects were sometimes observed and antagonism not demonstrated 
for any combination tested. The concentrations tested can be achieved in 
vivo. Enhanced activity of antifungal agents combined with these classes of 
antimicrobials has also been found for Candida species, although 
occasionally discrepancies were observed between in vitro and in vivo 
data.8,10 
In our study, we found synergic interaction when sulfadiazine were combined 
with itraconazole. No effect was observed in E. spinifera when the drug was 
used alone. The blood levels that can be reached in vivo (30–60 mg/L)4 
exceed the MIC of the combination of sulfadiazine and itraconazole. 
Synergic effects between sulphonamides and azoles were also found in 
Candida in which synergy was observed between ketoconazole and co-
trimoxazole.13 
In summary, the results presented here strongly suggest that quinolones or 
sulphonamides enhance the antifungal activity of drugs currently used for 
some isolates of E. spinifera. This provides potential alternative therapeutic 
options in infections from dematiaceous fungi. More investigations are needed 
to confirm these observations. 
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Abstract 
To develop new approaches for the treatment of invasive infections caused by 
Aspergillus fumigatus, the in vitro interaction between itraconazole and seven 
different nonantimicrobial membrane active compounds, amiodarone (AMD), 
amiloride (AML), lidocaine (LID), lansoprazole (LAN), nifedipine (NIF), 
verapamil (VER) and fluphenazine (FLU) against  7 itraconazole susceptible 
(ITZ-S) and 7 itraconazole resistant strains (ITZ-R), was evaluated according 
to checkerboard microdilution method based on the National Committee for 
Clinical Laboratory Standards Guideline M38-A. The nature and the intensity 
of the interactions were assessed using: nonparametric approach (fractional 
inhibitory concentration index model), fully parametric response surface 
approach (Greco model) of the Loewe additivity (LA) no-interaction theory, 
nonparametric (Prichard model) and a semiparametric response surface 
approaches of the Bliss independence (BI) no-interaction theory. Statistically 
significant synergy was found for the combination of ITZ and AMD, LAN and 
NIF, although with different intensities. The FIC indexes were 0.5 to 0.02 for 
ITZ-R-AMD; 0.5 to 0.06 for ITZ-R-LAN and 0.37 to 0.06 for ITZ-R-NIF. Using 
the BI-based model the strongest synergy was found for the combination of 
ITZ with AMD followed by ITZ and NIF. Most of the drugs alone 
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did not show a sigmoid dose response curve, and for this reason IC50 was not 
calculated a fit with the expected values not achieved. In general the 
combination of ITZ with calcium pump blockers displayed synergistic activity 
in vitro.  
 
 
Introduction 
Invasive aspergillosis causes approximately 30% of invasive fungal infections 
in patients treated for cancer (5). Until 1990 there was only one drug useful for 
treatment of invasive Aspergillus disease, amphotericin B, which has to be 
given intravenously and has a number of serious toxicities. In 1990 
itraconazole capsules became available that included Aspergillus species in 
the spectrum although the drug was mainly used in the prophylactic setting 
due to poor bioavailability (12). Ten years later an intravenous formulation of 
itraconazole became available allowing the drug to be used for the empiric or 
pre-emptive treatment of high risk patients. With the registration of 
voriconazole and caspofungin the arsenal of drugs available has further 
increased. However, despite antifungal therapy, mortality in patients with 
invasive aspergillosis remains very high and clearly new therapeutic 
approaches are needed. Combination therapy is one approach to improve 
efficacy of antimicrobial therapy in difficult-to-treat infections, such as HIV and 
mycobacterial infection. By analogy, the combination of itraconazole with 
others compounds could represent a possible approach for treating patients 
with invasive aspergillosis or those with strains with reduced susceptibility to 
antifungal agents. Resistance to antifungal azoles has been studied in yeasts 
and in molds, especially in Aspergillus. Resistance mechanisms include 
changes in cellular content of the azole (altered uptake or efflux mechanism), 
mutations in sterol desaturation during the ergosterol biosynthesis, and 
mutations in or elevated levels of 14α-demethylase (13,39). The recent 
discovery of drug-efflux-mediated resistance mechanisms in yeasts and 
Aspergillus opens new therapeutic concepts. It has been recognized that 
Candida albicans and Aspergillus nidulans express multidrug efflux 
transporter (MET) genes belonging to different classes, i.e. the ATP-binding-
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cassette transporters and the mayor facilitators (11, 44). The expression of 
these genes and their targeted deletion determine the level of azole 
resistance. 
In this study we investigated the in vitro interaction between itraconazole and 
different  nonantimicrobial membrane-active compounds against clinical 
itraconazole-resistant and susceptible strains using 4 different drug interaction 
models.  
 
Materials and Methods 
Strains. Fourteen clinical isolates of A. fumigatus were tested. These 
included 7 itraconazole susceptible (ITZ-S)  (V09-22, V09-23, AZN5161,  
AZN7820, AZN8248, AZN9339, AZN9362) and 7 itraconazole resistant (ITZ-
R) isolates (V09-18, V09-19, AZN5241, AZN5242, AZN7720, AZN7722, 
A.ZG7). The AZN and V09 numbered strains were obtained from the private 
collection of the Department of Medical Microbiology, University Medical 
Center Nijmegen and the strain AZG 7 was obtained from the University 
Hospital Groningen, The Netherlands (47). All isolates were subcultured on 
potato dextrose agar (PDA)  at  an interval of 5 to 7 days at 30°C . 
Quality Controls. C. parapsilosis (ATCC 22019) and C. krusei (ATCC 6815) 
were used  as quality control strains.   
Inoculum preparation. Conidia of the isolates were obtained from fresh 
cultures each time. Spores were collected with a cotton stick and suspended 
in sterile water. After the heavy particles were allowed to settle, the turbidity of 
the supernatants was measured spectrophotometrically (Spectronic 20D; 
Milton Roy, Rochester, N.Y.) at 530 nm and transmission was adjusted to  80 
to 82% and diluted to obtained a final inoculum of 0.4 x 104 to 5 x 104 CFU/ml. 
The inoculum size was verified by determination of the number of viable CFU 
after plating serial dilutions of the inoculum onto Sabouraud dextrose agar 
(SDA).   
Drugs. All solutions were prepared ex novo with powders from the same lot. 
The drugs used in this study were: itraconazole (ITZ) (Janssen-Cilag, Tilburg, 
the Netherlands), amiloride (AML), amiodarone (AMD), fluphenazine (FLU), 
lansoprazole (LAN), lidocaine (LID), nifedipine (NIF) and verapamil (VER) all 
from Sigma-Aldrich Chemie GmbH, Steinheim, Germany. The final 
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concentrations of the drugs ranged from: 0.03 to 16 µg/ml for ITZ; 0.13 to 8 
µg/ml for AMD and AML; 1.25 to 80 µg/ml for FLU and NIF; 0.6 to 40 µg/ml for 
LAN; 0.25 to 16 µg/ml for LID and 10 to 640 µg/ml for VER. All drugs were 
dissolved using dimethylsulfoxide (DMSO) as solvent. 
MIC. MICs were determinated by a broth microdilution method according to 
the National Committee for Clinical Laboratory Standards guidelines (M38-
P)(40). 
The drug dilutions were made in RPMI-1640 medium (with L-glutamine, 
without bicarbonate) (GIBCO BRL, Life Technologies, Woerden, The 
Netherlands); buffered to pH 7.0 with 0.165 morpholinepropanesulfonic acid 
(MOPS) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany). The test was 
performed in 96-well flat-bottom microtitration plates, which were kept at -
70°C until the day of testing. Each suspension of spores was diluted 1:50 in 
RPMI-1640 to obtain two times the desired inoculum. 
Growth was graded on a scale of 0 to 4 as follows: 4 indicated no reduction in 
growth, 3 indicated a 25% reduction of growth, 2 indicated a 50% reduction of 
growth, 1 indicated a 75% reduction of growth, and 0 indicated an optically 
clear well. The MIC-endpoint was defined as the lowest concentration of the 
drugs (alone or in combination) showing 50% inhibition of growth compared 
with that of the drug free control (MIC-2).  After agitation, the plates were 
incubated at 35°C for  48 h, after which the optical density (OD) was 
measured with a spectrophotometer (MS2 reader, Titertek-plus; ICN 
Biomedical Ltd., Basingstoke, United Kingdom) at 405 nm. The OD of the 
blank, to which a conidium-free inoculum had been added, was subtracted 
from the OD values. The percentage of growth for each well was calculated 
by comparing the OD of well with that of the drug-free control. 
Drug interaction. The in vitro interaction between ITZ and the blockers was 
studied using a two-dimensional checkerboard microdilution technique in 
sterile, 96-well flat-bottom microtitration plates described below. Each isolate 
was tested three times on different days.   
(i) Microtitration plates set up. For the combination studies, each drug was 
first serially diluted twofold in the corresponding solvents and then 100-fold in 
the medium according to the dilution scheme of NCCLS for water-insoluble 
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drugs in order to obtain 4 times the final concentration. 50 µl of each drug 
concentration of the azole was added to columns 1 to 10 and then 50 µl of 
each concentration of the corresponding blocker was added to rows A to G.  
Column 12  was the drug-free well that served as growth control.  
Drug interaction modeling. In order to assess the nature of the in vitro 
interaction between the drugs, the data obtained  were analyzed using four 
different models that were succesfully used in characterizing antifungal drug 
interaction (18, 36, 48). The models were parametric and non-parametric 
approaches of the following two no interaction theories: the Loewe additivity 
and the Bliss independence. In the Loewe additivity theory concentrations of 
the drugs, alone or in combination, that produce the same effect, are 
compared while in the Bliss independence based models the estimates of the 
combined effect based on the effect of the individual drugs were compared 
with those obtained in the experiment. 
(i) Loewe additivity. Loewe additivity is described by the following equation: 
1= dA/DA + dB/DB where dA and dB are the concentrations of the drugs A and B 
in the combination which elicit a certain effect and DA and DB the iso-effective 
concentrations of the drugs A and B when acting alone. The non-parametric 
approach is based on the fractional inhibitory concentration index (FIC) 
expressed with the following equation:  
  
 
 
 
where MICAalone and MICBalone are the concentrations of the drugs A and B 
when acting alone and CAcomb and CBcomb the concentrations of the drugs A 
and B at the iso-effective combinations (21).  Off-scale MICs were converted 
to the next highest or lowest doubling concentration. For each data set, the 
ΣFICmin was determined when the ΣFICmax was smaller than 4; otherwise the 
ΣFICmax was determined (21).  
The interpretation of the FICI was as follows: the synergistic effect, ≤ 0.5; 
additive effect >0.5 but  ≤1; indifferent effect  >1 but  ≤ 4;  and antagonistic 
effect > 4(15). In practice, synergy or antagonism calculated in this way is 
ΣFIC = FICA + FICB = 
CAcomb
MICAalone
CBcomb
MICBalone
+
Chapter  2.4 
 122
equivalent to a reduction or increase of at least two dilutions steps in the MIC 
of the combination compared to the MIC for the drugs alone.   
The fully parametric surface approach described by Greco et al. (18) was 
used based on the following equation: 
where E is the OD (dependent variable) at the drug concentrations DA and DB 
(independent variables), Emax is the maximal OD observed in the drug-free 
control, IC50,A and IC50,B are the drug concentrations producing 50% of the 
Emax, mA and mB are the slopes of the concentration-effect curves (Hill 
coefficient) for the drugs A and B, respectively and α is the interaction 
parameter which describes the nature of the interaction. This model was fitted 
directly to experimental data (the average OD among the replicates for all 
concentrations of the two drugs alone or in combination) with a non-weighted, 
non-linear regression analysis using the MODLAB program (MEDIMATICS, 
Maastricht, The Netherlands, www.medimatics.nl). Goodness of fit criteria 
included the 95% confidence interval (CI) of the fitted parameters, the R2, the 
sum of the squares, correlation and covariance matrices and the residual 
plots. 
When the parameter α as well as its 95% CI was positive statistically 
significant synergy was claimed while when α as well as its 95% CI was 
negative statistically significant antagonism was claimed. In any other case 
Loewe additivity was concluded. The additivity surface was simulated by fixing 
all parameters of the Greco model to values obtained after the model fitted to 
experimental data except α which was fixed at 0. The fitted experimental 
surface calculated by the Greco model was then subtracted from the additivity 
surface calculated as described above.  
(ii) Bliss independence. Bliss independence is described by the equation 
Ii=IA+IB-IAxIB where Ii is the predicted percentage of inhibition of the theoretical 
combination of the drugs A and B and IA, IB are the experimental percentages 
of inhibition of each drug acting alone, respectively. Since I=1-E where E is 
the percentage of growth and substituting to the former equation, the following 
equation is derived: Ei=EAxEB where Ei is the predicted percentage of growth 
1  = 
DA
IC50,A
E
Emax - E( )
1/mA
DB
IC50,B
E
Emax - E( )
1/mB
+
DA DB
IC50,A
E
Emax - E( )
0.5(1/mA + 1/mB)
IC50,B
α+
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of the theoretical combination of the drugs A and B, respectively and EA, EB 
are the experimental percentages of inhibition and growth of each drug acting 
alone, respectively. Interaction is described by the difference ∆E between the 
predicted and measured percentage of growth at various concentrations. 
Because of the nature of interaction, testing using microtiter plates with 
twofold dilution of either drug results in a ∆E for each drug combination. Using 
a three dimensional plot with ∆E depicted on the Z-axis, a surface plot is 
obtained. In the non-parametric surface approach described by Prichard et al. 
(42, 43), the EA and EB are obtained directly from the experimental data while 
in the semi-parametric surface approach (14, 18) these values are derived 
from fitting the Emax model to the concentration-effect curves of each drug 
alone. Thus, for the latter approach EA and EB are obtained by the following 
equation: EA,B = Emax x (D/IC50)m / [1+(D/IC50)m] where E, D, Emax, IC50 and m 
are the same parameters for drug A and B as described above. The 
parameters of the model were obtained by a non-weighted non-linear 
regression analysis using the GraphPad Prism Software (San Diego, CA). 
Data were normalized by using the percentages, and the maximum and the 
minimum of the Emax model corresponding with 100% and 0%, respectively, 
were kept constant. The fit of the model was interpreted using the run test and 
the R2 values. After the Emax model was fitted to the data, the parameters 
generated were used to calculate the no interaction surface for each replicate 
separately.  
For each combination of the two drugs in each of the three independent 
experiments, the observed OD of growth obtained from the experimental data 
was subtracted from the predicted OD calculated as described above for each 
model. When the average difference as well as its 95% CI among the four 
replicates was positive, statistically significant synergy was claimed, when the 
difference as well as its 95% CI was negative significant antagonism was 
claimed. In any other case Bliss independence was concluded. The values 
thus obtained for each combination were used to construct a three-
dimensional plot. Peaks above and below the 0 plane indicate synergistic and 
antagonistic combinations, respectively, while the 0 plane indicates no 
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statistically significant interaction. The contour plots were also constructed in 
order to visualize the drug concentrations producing an interaction.  
Since the plot only shows the interactions for each separate combination of 
the concentrations, a value is needed to summarize the interaction surface. 
This was done by calculating the sum percentage of all statistically significant 
synergistic (ΣSYN) and antagonistic interactions (ΣANT). Interactions with 
<100% of statistically significant interactions were considered weak, 100-
200% moderate, >200% strong as was described previously (36). In addition 
the number (N) of the statistically significant synergistic and antagonistic 
combinations among the 96 combinations of drug concentrations tested were 
calculated for each strain.  
 
 
Results 
The MIC of ITZ  based on 50% reduction of growth for C. krusei (ATCC 6815) 
and for C. parapsilosis (ATCC 22019)  were 0.5 and 0.25 µg/ml, respectively, 
which is within the reference range for quality control strains for ITZ. For the 
other drugs no reference range is established. Nevertheless, all the blocker 
drugs appeared to be not active against the Candida isolates. The final 
inoculum varied between 1.5 x 104 to 4 x 104 CFU/ml. The MIC for ITZ ranged 
from 16 to 32 µg/mL for ITZ-R A. fumigatus isolates and from 0.12 to 0.25 
µg/mL for ITZ-S isolates. AMD, AML, LAN, LID and VER were inactive in vitro 
against all stains tested. However, NIF and FLU were active with geometric 
mean MICs of 15 µg/mL (range 5 to 80 µg/mL) and 51 µg/mL (range 10 to 
160 µg/mL), respectively. 
 
Drugs in combination 
FICI evaluation and Bliss independent model. 
1) ITZ plus AMD. ITZ and AMD displayed additive interaction against most of 
the ITZ-S A. fumigatus strains, and were synergistic against two. The FICIs 
ranged from 0.5 to 1. However the combination was synergistic against 7 of 
the ITZ-R strains with the FICIs ranging from 0.02 to 0.5. With the BI method 
all ITZ-S strains displayed very low percentages of synergistic and 
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antagonistic interaction ranging between 3.61% and 44.3%  and between –
1.17% and –24.6%, respectively. For the ITZ-R strains synergistic interaction 
predominated with 108.7% to 1482.52% synergistic and –42.9% to –7.1% for  
antagonistic interaction. 
 
 
 
2) ITZ plus AML. ITZ and AML were synergistic against 2 ITZ-S A. fumigatus 
strains with FICIs ranging from 0.5 to 1, and against 5 strains using the BI 
model with variation between 219.16% to 52.7% and between –10.6% to –
89.4% for antagonistic interaction. Against 3 ITZ-R strains synergistic 
interaction was displayed using FICI and against  5 isolates using the BI 
model. (Data no shown)  
 
3) ITZ plus LAN. The interaction between ITZ and LAN  against ITZ-S A. 
fumigatus strains was less synergistic than against the ITZ-R A. fumigatus 
strains with FICI ranging from 0.5 to 0.75; using the BI model only 3 up to 7 
strains the drugs displayed synergistic interaction. Contrarily, the combination 
was more synergistic against the ITZ-R strains  for both methods evaluated  
(Table 2). 
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4) ITZ plus LID. Generally for this combination no interaction was observed 
for ITZ-S strains with FICI (range 0.5 to 1) whereas moderate synergistic 
interaction was found for ITZ-R strains with FICI (range 0.02 to 1) and also 
when the  BI model was used to characterize the interaction (fig 2).  
 
 
 
5) ITZ plus NIF. For this combination additive effect was observed for ITZ-S 
isolates using both methods (Table 3, Fig 1 and 2). Contrarily, the 
combination showed potent synergistic interaction in both models, with FICIs 
ranging from 0.06 to 0.37 and 134.26% to 1114.9% for the BI model against 
ITZ-R strains.  
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6) ITZ plus FLU. For this combination synergistic effect was observed, for 
only  3 ITZ-R strains  whereas for the other strains  additive or indifferent 
interaction was indicated using FICI index. In contrast, using the BI model the 
combination showed for all the strains variation between synergistic and 
antagonistic interaction resulting in statistical significant differences (Table 4 
and Fig 3a-b). 
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7) ITZ plus VER. Using FICI most of the strains had additive or indifferent 
interaction. With BI  model the combination was synergistic interaction in 4 
ITZ-S strains and 4 ITZ-R varies between synergistic and antagonistic effect 
(Data no shown). 
 
In general, when conventional antifungal agents were combined with pumps 
blockers, relatively high FICIs were observed against ITZ-R strains (>0.63),  
whereas lower values were found against ITZ-R strains (0.1-0.66)  (Fig 1). 
Using the BI model assuming the limit of 100% interaction, the highest 
synergistic interaction was observed against ITZ-R strains for ITZ-AMD 
followed by ITZ-NIF. Also,  proton pump inhibitors, such as lansoprazole,  
displayed synergistic interaction. Interesting was that fluphenazine displayed 
both activities (synergistic and antagonistic interaction) in resistant and 
susceptible strains of ITZ at the same time (Fig 2 and 3b).    
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Figure 1: FICI index between ITZ-S and ITZ-R for all drugs.
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Figure 3: Assessment of the in vitro interaction based on Bliss independence 
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Greco Model: 
The model failed to fit the data in all the combinations tested except for ITZ-
NIF. The program failed to fit the data in 8 cases for ITZ-AMD; 13 cases for 
ITZ-AML; 10 for ITZ-LAN; 10 for ITZ-LID; 12 for ITZ-FLU and in all cases for 
ITZ-VER. 
In case of ITZ-NIF, α values were ranged from 14.4 to 0.06; R2 values range 
from 0.84 to 0.97 for ITZ-S strains. For ITZ-R α was 8.21 (range 0.06 - 62.7) 
and R2 values ranged from 0.97 to 0.69. 
 
Semiparametric model of Bliss: 
In case of the semi-parametric approach the program failed to fit the data in 4 
occasions from the total of analyzed for ITZ-AMD with R2 for ITZ ranging from 
0.06 to 0.98 and for AMD from –0.37 to 0.81;  in 7 occasions for ITZ-AML with 
R2 ranging from 0.009 to 0.98 for ITZ and from 0.002 to 0.75 for AML; in 2 
occasions the data could no be fitted for the combination ITZ-LAN with R2 
ranging from 0.32 to 0.99 for ITZ and 0.002 to 0.8 for LAN. In case of the ITZ-
LID combination the data could not be fitted in 6 occasions to obtain the IC50; 
whereas in the others R2 were between 0.18 to 0.99 for ITZ and 0.06 to 0.69 
for LID. In the case of ITZ-VER IC50 was not calculate for 6 occasions with R2 
values ranged from 0.07 to 0.99 for ITZ and –2.5 to 0.89 for VER. 
IC50 was calculated for the combination ITZ-NIF and ITZ-FLU for all strains 
with R2 ranging from 0.53 to 0.99 from ITZ and 0.58 to 0.80 for NIF and 0.22 
to 0.89 for ITZ and 0.65 to 0.92 for FLU respectively.   
 
Discussion 
In mammalian cells, efflux mechanisms have been described. Particularly, the 
upregulation of P glycoproteins, which belong to METs of the ABC 
superfamily, is characteristic of cancer cells resistant to cytotoxic agents. 
Several authors have reported the inhibition of these proteins with different 
classes of drugs in multiresistant cancer cells (41). A similar experimental 
principle had already been investigated to reverse the chloroquine resistance 
in Plasmodium falciparum (4, 5, 25) or the resistance to quinolone antibiotics 
in Staphylococcus aureus (25). The present study sought to investigate the 
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effectiveness of several combinations of ITZ with MET inhibitors and with 
nonantimicrobial membrane-active compounds, such as antiarrhythmic agents 
and proton pump inhibitors. We observed that some of these compounds 
exhibit a potent antifungal effect when used in combination with ITZ. 
Amiodarone is the most complicated antiarrhythmic drug ever discovered. It 
has a number of electrophysiological effects that probably contribute to its 
antiarrhythmic effect. The drug is available for both, oral and intravenous use. 
The peak plasma concentration of this drug is 0.5 to 2.5 µg/ml (26) but in its 
steaty-state, the partition coefficient in tissues relative to plasma has been 
estimated to be 100 to above 1000 times the plasma level (35). In vitro activity 
of this drug alone against Aspergillus, Fusarium, Cryptococcus and Candida 
was demonstrated previously (9, 10). In our case we observed that the 
combination of this drug with ITZ showed synergistic activity against the ITZ-R 
strains independent of which model was used to characterize the interaction. 
There is as yet no explanation why this combination interacts synergistically, 
but this could be due to  inhibit on of mayor pumps including the efflux pumps 
or the calmodulin system. The concentration at which the synergistic 
interaction was observed is achievable in serum and in tissue and no mayor 
drug-drug interaction with ITZ was observed in patients, therefore the 
potential of this combination was rents further studies in vivo models.  
Amiloride, widely used clinically for its diuretic effect, have been recognized 
as a drug that possesses growth-inhibitory activity against bacterial cells (16, 
17). This agent is an inhibitor of various sodium transporters and is toxic to 
Schizosaccharomyces pombe at low concentrations (19). In this study no 
antifungal activity for this drug alone was observed. Also no significant 
interaction between ITZ and amiloride  against ITZ-S and ITZ-R strains was 
found. 
One new antifungal target could be the fungal plasma membrane H+-ATPase, 
which is an ATP-dependent proton pump. It plays a critical role in fungal cell 
physiology by regulating the intracellular pH, maintaining ionic balance and 
generating the electrochemical proton gradient necessary for nutrient uptake 
(45, 46). The H+-ATPase from Saccharomyces cerevisiae has been shown to 
be essential by gene disruption experiments (46) and it displays a number of 
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biochemical and genetic properties that make it attractive as a drug discovery 
target (38). The above mentioned pumps are present also in A. fumigatus  (6). 
These pumps can be blocked by different compounds, including the novel 
conjugated styryl ketone which was showed to be active tested in vitro and in 
vivo against A. fumigatus (31, 32), but no drug combination was tested 
against Aspergillus. Usefull were the proton pumps inhibitors, such us 
lansoprazole and omeprazole when combined with amoxicillin or erythromycin 
against Helicobacter pylori (37) which is supported by clinical evidence when 
was used against this pathogen in humans (29). Lansoprazole is a novel 
benzoimidazole proton pump inhibitor. Inhibition of the growth of C. albicans 
in vitro was demonstrated previously (3). In our study this drug alone was 
inactive against A. fumigatus but synergistic interaction was observed when 
combined with ITZ against ITZ-R A. fumigatus strains. 
The mechanism of action of lansoprazole is not clear. However, transmission  
electron microscopy revealed that exposure of eukaryotic cells to this drug 
resulted in the formation of free membranous vesicles and collapse of the cell 
surface structure suggesting an effect on the cell membrane (22). These 
effects could contribute to the observed interaction with ITZ against ITZ-R A. 
fumigatus strains, although the explanation for the synergism remains 
unclear.  
Nifedipine, a calcium entry-blocker, is used in angina pectoris and also in 
arterial hypertension. During the last years, its was demonstrated that some 
calmodulin inhibitors such as cyclosporin A and tacrolimus exert antifungal 
activity and potentiate the azole action in-vitro and in animal models (30, 33, 
34). Our data suggests a potent synergistic effect of nifedipine and ITZ  
against ITZ-R strains at clinical therapeutics levels (2). This effect was also 
observed when nifedipine or nimodipine were combined with ketoconazole 
against C. albicans (27, 28). This effect can be due to the fact that calcium 
and its binding protein calmodulin are known to modulate proliferation, 
differentiation and metabolism in a variety of cell types. Calmodulin is a small 
acidic Ca+2 binding protein, which is thought to induce intracellular Ca+2 fluxes 
into cellular responses (8). The concentration of free intracellular calcium can 
be increased in eukaryotic cells by opening of the voltage-dependent calcium 
channels (VDCC) allowing extracellular Ca2+ to enter the cell. Several 
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chemically distinct classes of organic compounds share the ability to inhibit 
calcium influx through VDCC (24). The VDCC channels are present in yeasts  
(7, 23, 49).  
Fluphenazine, a phenothiazine neuroleptic, is widely used in the treatment of 
psychotic illnesses (1) and displays antifungal activity alone against C. 
albicans  (20). Our results suggest that this drug exhibits antifungal activity at 
high concentrations. In combination with ITZ there is a paradoxical effect; in 
which the combination showed different interactions. This effect can be 
explained by the fact that fluphenazine is a subtract on and inductor of pumps 
specially CDR1 (Candida drug resistance) and CDR2 (20) at different 
concentrations. Fluphenazine antagonized the azole activity especially at low 
concentration of both drugs (fig 3 b), an effect that reflects the induction of 
pumps and the reduction of the activity of the azoles. Contrarily, at high 
concentrations the antagonistic activity was reproducibly replaced by additive 
or synergistic interaction. This effect also has been demonstrated against C. 
albicans using agar techniques and molecular methods (20). 
Finally, parametric models as Greco model and semiparametric models as 
Prichard, have been carefully evaluated, especially if the concentration 
response curves of one of the drugs does not follow a sigmoid and 
consequently the IC50 and fit of the data obtained cannot be achieved. In this 
case non-parametric approaches could be useful. More than one effect can 
be present and in this respect parametric approaches as Greco model is not 
useful since the Greco theory assumes that only one combination effect is 
present. On the other hand, the complexity of drugs that can be active alone 
or in combination against eukaryotic cell, have to be analyzed carefully.  
In conclusion, this is the first study in which the activity of ITZ in combination 
with nonantibacterial membrane active compounds was investigated  against 
A. fumigatus. Several synergistic combinations were identified that warrant 
further investigation in vivo in order to develop new strategies for the 
treatment of invasive aspergilosis.  
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Summary 
 
During the last decade, the incidence of fungal infections are increasing. In 
vitro susceptibility tests are a tool to evaluate the activity of antifungal agents 
against fungi and despite the improvement of different methodologies, lack of 
correlation between in vitro and in vivo studies still is problematic. 
Due to the progress made in the fields of intensive care, hemato-oncology 
and transplantation in particular, the number of immunocompromised patients 
has increased. Although modern antibacterial chemotherapeutic agents 
contribute a great deal to improved prognosis, increasing numbers of 
immunocompromised patients are at risk for systemic fungal infection. Fungal 
infections have been a major therapeutic challenge. The therapeutic arsenal 
has been limited and the use of drugs has been restricted due to toxicity or 
unfavorable pharmacokinetic profiles. Furthermore resistance has been seen 
emerging following treatment of Candida albicans infections in HIV-infected 
patients with  triazoles. There is also some evidence that the spectrum of 
fungi involved in human infection is shifting from Aspergillus fumigatus and 
Candida to uncommon fungi. The activity of conventional and new antifungal 
agents against these pathogens is limited or unknown. There is evidence that 
some drugs targeted at pathogens other than fungi exhibit antifungal activity. 
In addition, drugs used for the treatment of conditions other than infectious 
diseases might exhibit antifungal activity since fungi and human cells share 
common pathways, both being eukaryotic. This is of interest since these 
drugs might be useful for treatment of fungal infections alone or in 
combination with antifungal or interact with potentially new targets.   
In Chapter 1.1 the antifungal activity of non-antifungal agents alone or in 
combination with conventional antifungal drugs was reviewed. 
In Chapter 1.2 the in vitro susceptibility of 70 strains of Aspergillus species 
was evaluated against 7 different sulfa drugs and pentamidine using a 
microdilution method with RPMI 1640 and yeast nitrogen base media. The 
MICs obtained with RPMI 1640 were significantly higher than those with yeast 
nitrogen base. Sulfamethoxazole, co-trimoxazole, sulfamethoxypyridazine and 
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sulfadiazine  were active against the 20 A. fumigatus isolates. Lower MICs 
were observed against A. niger and pentamidine and sulfamethoxazole 
showed the highest activity against A. nidulans. All drugs were less active 
against A. ustus and A. terreus except for pentamidine. Because invasive 
aspergillosis is encountered relatively infrequently in HIV - infected patients, 
we hypothised that prophylaxis for Pneumocystis carinii pneumonia (PCP) 
might also prevent invasive Aspergillus infections. In Chapter 1.3 the 
literature was reviewed for cases of invasive aspergillosis in HIV-infected 
patients that developed the infection during prophylaxis for PCP. Only 18 
cases have been described in the literature. The probability of developing 
invasive aspergillosis in patients who received alternative PCP prophylaxis 
was much higher than for those on prophylaxis with TMP-SMZ, indicating 
some activity of this combination in vivo.  
Phenothiazines and thiothixene are antipsychotic drugs which have multiple 
effects on eukaryotic cells, including modification of membranes, alteration of 
cyclic nucleotide metabolism and also binding to calmodulin which regulates 
many intracellular processes. In Chapter 1.4 we investigated the antifungal 
activity of seven antipsychotic drugs against 202 yeast and mold isolates with 
variable resistance to conventional antifungal agents. Trifluopherazine, 
chlorpromazine, fluphenazine and chlorprothixene displayed antifungal activity 
against C. albicans, C. krusei, C. glabrata, zygomycetes, Aspergillus species,  
S. apiospermum and S. prolificans. The results of this study demonstrated 
that antipsychotic drugs are active in vitro and this activity might be of interest 
for antifungal drug discovery. 
In addition, in Chapter 2.1 the in vitro interaction between amphotericin B and 
either rifampicin, flucytosine, or terbinafine and between terbinafine and 
voriconazole was tested against 35 strains of zygomycetes. The interaction 
between amphotericin B and rifampicin was synergistic in 69% of cases and 
additive in 31% of cases. No antagonism was observed.  
In chapter 2.2, the combination of antifungal drugs with different mechanisms 
of action was evaluated as a possible and promising approach to treatment of 
invasive scedosporiosis. In this context, pentamidine and amphotericin B were 
combined. Both drugs showed synergistic interaction in 30 clinical S. 
prolificans isolates with either the fractional inhibitory concentration index or 
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with response surface modeling. Amphotericin B alone was inactive against 
all the isolates. The geometric mean MIC for pentamidine was 57 µg/ml 
(range, 8 to 256 µg/ml; MIC50, 64 µg/ml; MIC90, 128 µg/ml). The combination 
was synergistic against 28 of 30 isolates (93.3%) by FICI analysis and against 
30 of 30 (100%) by response surface modeling analysis. 
In addition, antimicrobial drugs such us sulfonamides, rifampicin, macrolides 
and quinolones were studied alone or in combination with polyenes or azoles 
in vitro. In Chapter 2.3 amphotericin B was combined with flucytosine and 
ciprofloxacin, while itraconazole was combined with ciprofloxacin, 
levofloxacin, lomefloxacin and sulfadiazine against E. spinifera isolates. 
Synergistic effects were observed for the combinations of: itraconazole plus 
ciprofloxacin or levofloxacin; and amphotericin B plus ciprofloxacin or 
flucytosine.   
Chapter 2.4 is focussed on new approaches for the treatment of invasive 
infections caused by A. fumigatus. For this reason the in vitro interaction 
between itraconazole and seven different non-antimicrobial membrane active 
compounds, amiodarone (AMD), amiloride (AML), lidocaine (LID), 
lansoprazole (LAN), nifedipine (NIF), verapamil (VER) and fluphenazine (FLU) 
against  seven itraconazole susceptible (ITZ-S) and seven itraconazole 
resistant strains (ITZ-R), was evaluated with a checkerboard microdilution 
method. The nature and intensity of the interactions were assessed using: 1) 
a nonparametric approach (fractional inhibitory concentration index model); 2) 
a fully parametric response surface approach (Greco model) of the Loewe 
additivity (LA) no-interaction theory;  3) a nonparametric (Prichard model) and 
a semiparametric response surface approaches of the Bliss independence 
(BI) no-interaction theory. Statistically significant synergy was found for the 
combination of:  ITZ and AMD, and LAN and NIF, although with different 
intensities. The FIC indexes were 0.5 to 0.02 for ITZ-R-AMD; 0.5 to 0.06 for 
ITZ-R-LAN and 0.37 to 0.06 for ITZ-R-NIF. Using the BI-based model the 
strongest synergy was found for the combination of ITZ with AMD followed by 
ITZ and NIF. Most of the drugs alone did not show a sigmoid dose response, 
and it is for this reason that the IC50 was not calculated and a fit of the data 
could not be achieved using the parametric approaches. In general the 
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combination of itraconazole with calcium pump blockers displayed in vitro 
synergistic activity.  
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Samenvatting 
 
De incidentie van schimmelinfecties is in de afgelopen 20 jaar sterk 
toegenomen. In vitro gevoeligheidsbepalingen zijn een belangrijk hulpmiddel 
geworden in het laboratorium om een indruk te krijgen over de effectiviteit van 
antischimmel middelen. Echte ondanks de technische vooruitgang in de 
verschillende in vitro methodes is er nog steeds weinig correlatie tussen in 
vitro onderzoek en de werkzaaamheid in vivo. Door de toename in medisch 
technisch handelen zoals in de vakgebieden intensieve zorg, hemato-
oncologie en transplantatie geneeskunde zijn er een groot aantal  patienten 
met verminderde weerstand bijgekomen. Moderne antibacteriële 
chemotherapie heeft bijgedragen tot een betere prognose van deze patiënten 
maar de keerzijde van de medaille is dat deze patiënten een toenemend risico 
lopen op een systemische schimmelinfectie. Succesvolle behandeling van 
schimmelinfecties was en is een lastige opgave. Dit is vooral toe te schrijven 
aan het kleine aantal effectieve middelen op de markt en de vaak ernstige 
bijwerkingen die met behandeling gepaard gaan. Een ander probleem is dat 
resistente gisten zich hebben ontwikkeld, vooral bij HIV geinfecteerde 
patienten die met triazolen zijn behandeld. Tot slot zijn er aanwijzingen dat de 
verwekkers van deze opportunistische infecties bij de mens veranderen van 
de Aspergillus en Candida soorten naar meer zeldzamer voorkomende 
schimmels. Over de werkzaamheid van de oude en nieuwe 
antischimmelmiddelen tegen deze opkomende  zeldzame schimmels is weinig 
tot niets bekend. Er zijn aanwijzingen dat middelen die zijn ontwikkeld tegen 
ziekteverwekkers anders dan schimmels ook antischimmelactiviteit bezitten. 
Bovendien kunnen geneesmiddelen die gebruikt worden buiten het veld van 
de infectieziekten ook antischimmelactiviteit hebben omdat zowel humane 
cellen als schimmels eukaryoten zijn en dus dezelfde metabole processen  
hebben. Dit is van potentieel belang omdat deze geneesmiddelen direct of in 
combinatie met bekende antischimmelmiddelen een effect zouden kunnen 
hebben op potentieel nieuwe aangrijpingspunten 
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In Hoofdstuk 1.1 is een uitgebreide beschrijving opgenomen van de 
antischimmelactiviteit van geneesmiddelen die niet als zodanig toegepast 
worden en de effectiviteit van de gecombineerde toepassing van deze 
middelen met geregistreerde antischimmel middelen. In Hoofdstuk 1.2 is de 
in vitro gevoeligheid  van 70 Aspergillus isolaten voor 7 verschillende sulfa 
preparaten en pentamidine beschreven, gemeten met een microdilutie 
methode in RPMI 1640 of yeast nitrogen base (YNB) medium. De gevonden 
MIC’s met RPMI 1640 waren significant hoger dan die na gebruik van  YNB.  
Sulfamethoxazole, co-trimoxazole, sulfamethoxypyridazine en sulfadiazine 
waren alle werkzaam tegen 20 A. fumigatus isolaten. Lagere MIC waarden 
werden gevonden voor A. niger en pentamide terwijl sulfamethoxazole de 
beste activiteit liet zien tegen A. nidulans. Behalve pentamidine waren alle 
andere geteste middelen minder actief tegen A. ustus en A. terreus. Omdat 
invasieve aspergillose een zeldzame aandoening is bij HIV geinfecteerde 
patienten werd de hypothese geponeerd dat het profylactisch gebruik van 
middelen tegen P. carinii pneumonie (PCP) ook beschermd tegen invasieve 
Aspergillus infecties. In Hoofdstuk 1.3 is een literatuurstudie opgenomen 
naar gepubliceerde casus van invasieve aspergillose bij HIV geinfecteerde 
patienten met PCP profylaxe. Slechts 18 casus zijn beschreven in de 
literatuur. De kans om invasieve aspergilose op te lopen bij patienten die 
andere PCP profylaxe kregen dan co-trimoxazole was vele malen hoger dan 
bij patienten op standaard co-trimoxazole profylaxe. Dit suggereert enige 
activiteit van deze combinatie in vivo tegen Aspergillus. Phenothiazines en 
thiothixenen zijn antipsychotica met meerdere effecten op eukaryote cellen, 
zoals verandering van membraanstructuur, invloed op het cyclisch nucleotide 
metabolisme en binding aan calmoduline dat vele intracellulaire processen 
reguleerd. In Hoofdstuk 1.4 is de antischimmelactiviteit beschreven van 7 
antipsychotica tegen 202 gist- en schimmel isolaten met verschillende 
resistenties tegen conventionele antischimmelmiddelen. Trifluopherazine, 
chlorpromazine, fluphenazine en chlorprothixene bleken activiteit te hebben 
tegen C. albicans, C. krusei, C. glabrata, zygomyceten, Aspergillus species, 
S. apiospermum en S. prolificans. Het feit dat antipsychotica in vitro actief 
bleken te zijn tegen schimmels kan van invloed zijn op het ontwikkelen van 
nieuwe antischimmel middelen met verwantschap aan de genoemde 
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antipsychotica. In Hoofdstuk 2.1 is de in vitro interactie  tussen 
amphotericine B en rifampicine, flucytosine of terbinafine en tussen 
terbinafine en voriconazol beschreven by 35 zygomyceet isolaten. De 
interactie tussen amphotericine B en rifampicine was synergistisch in 69% 
van de isolaten en additief bij 31%. Er werd geen antagonisme gevonden. In 
Hoofdstuk 2.2 werden antischimmelmiddelen met verschillende 
aangrijpingspunten op de schimmel met elkaar gecombineerd tegen klinische 
Scedosporium isolaten, die notoir slecht te behandelen zijn. De combinatie 
van pentamidine en amphotericine B liet zien dat er synergistische interactie 
was in 30 S. prolificans isolaten zowel na evaluatie van de resultaten met de 
FIC index of door middel van response surface modelling. Amphotericine B 
alleen was niet werkzaam tegen deze isolaten. Het geometrisch gemiddelde 
voor pentamidine was 57 ugr/ml (spreiding 8 tot 256 ugr/ml; MIC50, 64 ugr/ml; 
MIC90 128 ugr/ml). De combinatie van amphotericine B en pentamidine was 
synergistisch voor 28 van de 30 isolaten wanneer de FIC analyse werd 
toegepast en voor alle isolaten na response surface modelling. Bovendien 
werden andere antimicrobiele middelen zoals sulphonamiden, rifampicine, 
macroliden en quinolonen alleen en in combinatie met polyenen of azolen in 
vitro getest. In Hoofdstuk 2.3 worden de resultaten beschreven van de in 
vitro gevoeligheid van E. spinifera isolaten voor amphotericine B 
gecombineerd met flucytosine  of ciprofloxacine en voor itraconazole 
gecombineerd met ciprofloxacine, levofloxacine, lomefloxacine en 
sulfadiazine. Synergisme werd gevonden voor de combinaties van 
itraconazole en ciprofloxacine of levofloxacine en de combinatie 
amphotericine B met ciprofloxacine of flucytosine. In Hoofdstuk 2.4 zijn 
nieuwe combinaties getest die mogelijk gebruikt kunnen worden bij de 
behandeling van invasieve infecties veroorzaakt door A. fumigatus. 
Itraconazole werd in vitro sequentieel gecombineerd met 7 verschillende 
membraan actieve stoffen die geen bekende antimicrobiele activiteit hebben. 
Deze middelen amiodarone (AMD), amiloride (AML), lidocaine (LID), 
lansoprazole (LAN), nifedipine (NIF), verapamil (VER) en fluphenazine (FLU) 
zijn getest met een checkerboard microdilutie methode tegen 7 itraconazol 
(ITZ) gevoelige en 7 itraconazol  resistente (ITZ-R) A. fumigatus isolaten. Het 
effect en de werkzaamheid werden beoordeeld met 1) een niet parametrische 
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benadering (FIC), 2) een totaal parametrische response surface benadering 
(Greco model) van de Loewe additieve (LA) geen interactie theorie, 3) een 
niet parametrische (Pritchard model) en een semi-parametrische response 
surface benadering van de Bliss onafhankelijke (BI) geen interactie theorie  
Statistisch significante synergie werd in wisselende mate gemeten voor de 
combinaties  ITZ en AMD of LAN of NIF. De FIC indices waren 0,5 tot 0,02 
voor  ITZ-R-AMD; 0,5 tot 0,06 voor ITZ-R-LAN en 0,37 tot 0,06 voor ITZ-R-
NIF. Bij gebruik van het BI model werd de sterkste synergie gevonden voor de 
combinatie van ITZ met AMD gevolgd door ITZ en NIF. Bij afzonderlijk testen  
lieten de meeste middelen niet de gebruikelijke S-vormige dosis-respons 
curves zien. Daarom werd de IC50 niet berekend  en met de parametrische 
benadering konden de verkregen data niet in het model worden ingebracht. 
Uit deze`studie kan geconcludeerd worden dat de combinatie van 
itraconazole met calciumpomp blokkers in vitro synergie liet zien. 
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Resumen 
 
En los últimos años, la incidencia de infecciones fúngicas se ha incrementado 
debido a los avances de la medicina moderna. Con el uso más extendido de 
drogas inmunosupresoras y la quimioterapia se observa un aumento de las  
complicaciones infecciosas. El número de pacientes inmunocomprometidos 
ha aumentado debido al incremento del número de transplantes, a la 
internación en unidades de terapia intensiva o debido  a enfermedades 
hemato-oncológicas y su tratamiento. Por esto,  microorganismos 
ambientales y saprobios se convirtieron en patógenos que podrían causar 
infecciones mortales. Este aumento también se corresponde con el 
incremento  de las micosis sistémicas oportunistas, que hizo necesario 
desarrollar fármacos más eficaces para el tratamiento de estas infecciones. 
La disponibilidad de drogas antifúngicas es escasa y el uso está restringido 
debido su toxicidad y a su desfavorable perfil farmacocinético. Además ha 
aumentado la resistencia a las drogas azólicas en infecciones producidas por  
Candida albicans  en pacientes HIV positivos. Los hongos más comunes 
causantes de enfermedades fúngicas están variando desde Aspergillus 
fumigatus o Candida a hongos menos comunes y menos sensibles a las 
drogas antifúngicas convencionales, el uso de nuevos compuestos es 
limitada y se encuentran en estudio. 
 Por este motivo se hizo necesario, estandarizar técnicas que permitan 
detectar resistencia a las drogas antifúngicas. Por el momento estas pruebas 
muestran cierta correlación con la evolución clínica de los enfermos.  
A pesar de que los agentes quimioterápeuticos contribuyen a mejorar el 
pronóstico, el incremento de pacientes de alto riesgo aumenta la probabilidad 
de infecciones fúngicas sistémicas. 
Ya que las células humanas y fúngicas comparten en muchos casos vías 
metabólicas similares,  debido a su naturaleza eucariota, existe la posibilidad 
de encontrar actividad antifúngica en drogas que actualmente se usan con 
otros fines. Existe evidencia de que una gran variedad de drogas con 
actividad antifúngica podría ser de interés para el desarrollo de nuevos 
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compuestos capaces de ser útiles para el tratamiento,  solas o en 
combinación con  agentes antifúngicos clásicos.  
En el Capítulo 1.1, se detalla una revisión de la actividad antifúngica de 
drogas frecuentemente empleadas en cardiología, psiquiatría, 
gastroenterología o anestesiología. Se describe la actividad de estas drogas 
sólas o en combinación con antifúngicos clásicos contra un número variable 
de patógenos incluyendo levaduras y hongos filamentosos. 
En el Capítulo 1.2, se ha evaluado la actividad in-vitro de 7 diferentes tipos 
de sulfas en pentamidine en 70 cepas de Aspergillus spp. usando el método 
de microdilución en placa y empleando  dos medios de cultivo: RPMI-1640 y 
medio base de extracto de levadura (YNB). En el medio de RPMI-1640, la 
concentraciones inhibitoria mínima (CIM) ha sido más elevada que en YNB. 
Veinte cepas de A. fumigatus han sido susceptibles a sulfametoxazol, 
cotrimoxazol, sulfametoxipiridazina y sulfadiazina. Pentamidina y 
sulfametoxazol fueron más activas para A. nidulans que para A. niger. Todas 
las drogas estudiadas fueron poco activas para A. ustus y A. terreus, excepto 
pentamidina. 
A partir de los resultados obtenidos en el capítulo anterior y debido a que no 
es frecuente que pacientes HIV positivos desarrollen aspergilosis invasiva, 
dada la baja frecuencia de neutropenia en estos pacientes, hemos analizado 
la posible influencia de la profilaxis utilizada para prevenir  la neumonía a P. 
carinii, y el impacto clínico que ésta podría tener en la aparición de asperilosis 
en esta población de pacientes. En el Capítulo 1.3, se realizó una revisión de 
la bibliografía de casos de pacientes HIV positivos que desarrollaban 
aspergilosis invasiva durante la profilaxis para P. carinii. Se observa que la  
aspergilosis invasiva en pacientes que reciben drogas no efectivas in vitro 
para Aspergillus presentan una incidencia mayor a padecer aspergilosis que 
aquellos que recibieron profilaxis con sulfametoxazol, lo que indicaría que 
este compuesto podría poseer cierta actividad  in vivo. 
Las fenotiazinas y tiotixenos son drogas antipsicóticas que poseen múltiples 
efectos en células eucariontes, como ser, modificación en las membranas, 
alteración del metabolismo del ciclo nucleotídico o la unión a calmodulina, 
responsable de varios procesos intracelulares. En el Capítulo 1.4, se ha 
investigado la actividad de siete drogas antipsicóticas contra 202 aislamientos 
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de levaduras y hongos filamentosos que presentaban resistencia variable a 
los antifúngicos clásicos. Se observó que la trifluperazina, clorpromazina, 
flufenazina y clorprotixeno fueron activas para C. albicans, C. krusei, C. 
glabrata, zygomycetes, Aspergillus spp., S. apiospermum y S. prolificans. 
Estos resultados demostraron que esta clase de drogas poseen actividad 
antifúngica y su estudio podría ser de gran interés para el desarrollo de 
nuevos compuestos. 
En el Capítulo 2.1, se estudiaron las siguientes combinaciones: anfotericina 
B con rifampicina, flucitosina y terbinafina y por último terbinafina con 
voriconazol, en 35 cepas de zygomycetes. Se observó acción sinérgica para 
la combinación entre anfotericina B y rifampicina en el 69% de los casos y 
efecto aditivo en el 31%. No se observó antagonismo en ninguna 
combinación. 
En el Capítulo 2.2 se han evaluado drogas que posean diferentes 
mecanismos de acción y que en combinación podrían ser útiles como una 
terapéutica alternativa al tratamiento de las scedosporonosis. La combinación 
utilizada fue anfotericina B con pentamidina y se ha observado acción 
sinérgica en 30 aislamientos clínicos de S. prolificans.  Para evaluar la 
intensidad de la combinación se utilizaron distintos modelos tanto 
paramétricos (basado en el modelo propuesto por Greco) como no 
paramétricos (basado en la obtención del índice de la concentración 
inhibitoria fraccionada). Anfotericina B presentó muy poca actividad in vitro 
contra esta patógeno cuando la droga se utilizó sola. La media geométrica de 
CIM para pentamidina ha sido 57 µg/ml (rango de 8 a 256 µg/ml; la CIM50, 64 
µg/ml y la CIM90, 128 µg/ml). La combinación fue sinergística en el 93.3% de 
los casos (28/30 cepas) utilizando el FICI y en el 100 % de los casos (30/30 
cepas) utilizando el modelo postulado por Greco. 
Adicionalmente, otras drogas antimicrobianas como las sulfonamidas, 
rifampicina o quinolonas fueron estudiadas in vitro, sólas o en combinación 
con polienos o azoles. En el Capítulo 2.3, la anfotericina B se combinó con 
flucitosina y ciprofloxacina; mientras que itraconazol se combinó con 
ciprofloxacina, levofloxacina, lomefloxacina y sulfadiazina en cepas de E. 
spinifera. Se observó efecto sinérgico para las siguientes combinaciones: 
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itraconazol con ciprofloxacina o levofloxacina y anfotericina B con 
ciprofloxacina o flucitocina. 
Con el objetivo de buscar nuevas alternativas en el tratamiento de 
aspergilosis invasivas causadas por A. fumigatus, en el Capítulo 2.4, se han 
evaluado las siguientes combinaciones utilizando el método de microdilución 
en placas:  itraconazol se combinó con siete compuestos no antimicrobianos, 
frecuentemente usados como antiarrítmicos, antipsicóticos,  diuréticos o 
anestésicos. Los compuestos empleados fueron: amiodarona (AMD), 
amiloride (AML), lidocaína (LID), lansoprazol (LAN), nifedipina (NIF), 
verapamilo (VER) y flufenazina (FLU). 
Se utilizaron 7 cepas susceptibles a itraconazol (ITZ-S) y 7 cepas resistentes 
(ITZ-R). Las interacciones entre las drogas fueron evaluadas utilizando 
distintos modelos: 1) No paramétrico (FICI y modelo de Prichard); 2) 
Paramétrico (modelo de Greco) y 3) Semi-paramétrico (modelo de Bliss). Se 
observó acción sinérgica estadísticamente significativa para la combinación  
ITZ y AMD e ITZ y NIF, aunque con distintas intensidades. Los FICI fueron de 
0.5 a 0.02 para la combinación ITZ y AMD; 0.5 a 0.06 para la combinación 
ITZ y LAN y 0.37 a 0.06 para la combinación ITZ y NIF. Analizando los 
resultados con el modelo de Bliss el mayor sinergismo fue encontrado para la 
combinación de ITZ con AMD seguida por la combinación ITZ y NIF. En los 
modelos paramétricos y semi-paramétricos, el estudio de la actividad de las 
drogas solas está basado en la obtención de una curva de tipo sigmoidea 
dependiente de la concentración de las mismas. La mayoría de las drogas 
sólas no siguieron una respuesta sigmoidea, por lo que la concentración 
inhibitoria 50 (IC50) no pudo ser calculada. Estos modelos deberían ser 
evaluados cuidadosamente para su empleo para el estudio de combinación 
de drogas in vitro.  
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Future perspectives 
 
Given the increasing incidence of invasive fungal infection and the limited 
efficacy of currently available antifungal agents, new approaches are needed. 
A broad spectrum of drugs and natural products produced by microorganisms 
might be investigated for their antifungal activity. Although recently new drugs 
have been registered for treatment of invasive fungal infections, including 
voriconazole and caspofungin, the number of patients that fail therapy 
remains very high. Another aspect which is becoming increasingly important 
are the costs of treatment. Several new agents including lipid formulations of 
amphotericin B, the new azoles and echinocandins are expensive when given 
as monotherapy. Combinations of these drugs will increase the costs even 
further which is a significant problem especially in the developing countries. 
In this thesis we have presented a considerable number of conventional drugs 
that exhibit antifungal activity and are in use in clinical practice for indications 
other than treatment of infectious diseases. However, the currently published 
data are only on in vitro activity. There is very limited clinical data that indicate 
any clinically relevant activity of non-antifungal compounds in patients with 
fungal infections. In vitro techniques that allow detailed analysis of drug 
interaction against yeasts and molds have recently been developed and are 
used to determine the nature of the interaction. This would help to screen a 
large number of potential drug combinations and select promising 
combinations for further studies in animal experiments. Examples of 
promising combinations are azoles with terbinafine and amphotericin B with 
pentamidine. Also amphotericin B combined with rifampicin appeared to be a 
beneficial combination against some zygomycetes. 
In addition, animal studies that take into account pharmacodynamic 
parameters need to be performed. Based on these data new approaches to 
the management of invasive fungal infections can be designed. 
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